February 2026
Longevity research from February 2026, curated and analyzed through the EDGE Framework.
Does lowering cholesterol harm the brain?
A large genetic study finds that lifelong reductions in atherogenic lipoproteins are associated with lower dementia risk, contradicting the concern that cholesterol-lowering strategies harm cognitive function. This evidence clarifies a persistent misconception in longevity planning.
Digital Engagement and Successful Aging: A Longitudinal Analysis of Older Adults in China
Digital engagement demonstrates bidirectional associations with successful aging in Chinese adults aged 60–75 over seven years, with baseline digital use predicting improvements in physical function, cognitive performance, and subjective well-being, while successful aging outcomes also predict sustained digital engagement. This longitudinal evidence suggests digital literacy and consistent technology use function as modifiable factors supporting multiple dimensions of aging outcomes.
Cross-Cultural Perspectives on Smartphone Use in Older Adults: A Thematic Analysis of Persian and English-Language X Platform Discussions
Cross-cultural analysis of social media discussions reveals that smartphone use in older adults functions as a vector for both social connection and cognitive load—with Persian and English-language communities expressing distinct concerns about attention, isolation, and autonomy. The framing of technology's role in aging demonstrates how cultural context shapes perception of cognitive and emotional demand.
Denali Therapeutics reports 2025 results, highlights pipeline progress
Denali Therapeutics reported $176.4 million in 2025 revenue with expanded clinical development across neurodegenerative programs, including Phase 2/3 advancement of DNL310 for lysosomal storage disorder and progression of Alzheimer's and ALS candidates. The company's $1.84 billion cash position supports operations through 2030, enabling sustained investment in blood-brain barrier delivery technology and central nervous system therapeutics.
Mesoblast highlights Ryoncil profits supporting pipeline growth
Mesoblast reports that commercial revenues from Ryoncil, an approved cell therapy for steroid-refractory acute graft-versus-host disease, are funding expansion of its pipeline focused on inflammatory, immune-mediated, cardiovascular, and chronic pain conditions. The company's financial self-sufficiency through product sales reduces reliance on external financing while enabling continued clinical development.
Tectonic Therapeutic reports 2025 financial results and pipeline progress
Tectonic Therapeutic reported 2025 revenues of $65.2 million with R&D spending at $96.3 million, maintaining $158.9 million in cash reserves through mid-2027. The company is advancing targeted protein degradation candidates in oncology and CNS disorders with near-term clinical data catalysts expected in 2026.
Promoting Adaptation to Caregiving Challenges: A Qualitative Study of Dementia Caregiving Specialists
Dementia caregiving specialists employ structured approaches to help family caregivers develop mastery over the behavioral and emotional challenges of dementia care. Understanding how these specialists facilitate caregiver adaptation provides actionable insights for reducing caregiver burden and improving outcomes in neurodegenerative disease management.
Spontaneous speech enables scalable digital phenotyping of physical functional deficits in aging
Analysis of spontaneous speech patterns—including acoustic features, linguistic markers, and speech rate—can identify physical functional decline in aging populations with accuracy comparable to formal physical assessments. This approach enables remote, scalable detection of mobility and strength deficits without requiring in-person testing.
Measuring intrinsic capacity at scale
Stanford-led THRIVE coalition secured $34.5 million to develop the first FDA-grade Intrinsic Capacity score, a composite measure integrating wearables, blood biomarkers, and functional assessments to predict 20-year health outcomes. This addresses the field's critical gap: the absence of regulatory-grade measurement infrastructure for aging itself, moving beyond disease-specific endpoints toward quantifiable functional decline.
How billionaires die
Analysis of 389 billionaire deaths between 2015 and 2025 reveals that extreme wealth does not substantially extend lifespan. Despite access to elite healthcare, experimental therapies, and optimization resources, billionaires die at ages comparable to populations in high life expectancy countries, with approximately 90% of documented deaths following aging-related disease patterns.
A cellular atlas of aging comes into focus
A single-cell chromatin atlas across 21 tissues reveals that aging involves coordinated, sex-specific regulatory remodeling rather than random molecular decay. The coordinated shifts across anatomically distinct organs suggest systemic drivers—circulating signals, immune tone, endocrine cues—offering both mechanistic insight and practical constraints for intervention design.
Cellular Reprogramming: The Expert Roundup
Cellular reprogramming—the process of resetting aged cells to younger functional states through partial application of reprogramming factors—represents a fundamental shift in how aging is understood: not as irreversible damage accumulation, but as a modifiable biological state. Clinical trials are imminent, and the field has moved from theoretical elegance to therapeutic platform with potential applications across age-associated diseases.
Nautilus debuts Voyager platform in push toward next-gen proteomics
Nautilus Biotechnology unveiled Voyager, a benchtop proteomics platform that analyzes individual protein molecules at scale rather than averaging protein populations, enabling detection of proteoforms—subtle molecular variants—that distinguish healthy aging from disease progression. Validation at the Buck Institute for Research on Aging demonstrates reproducible tau proteoform quantification, addressing a critical gap in biomarker discovery for neurodegenerative diseases.
IFN-γ emerges as a simple blood clue to Alzheimer’s
Interferon-gamma (IFN-γ), a common immune signaling molecule, emerges as a blood-based biomarker capable of distinguishing Alzheimer's disease from healthy aging with high accuracy, particularly in individuals carrying the APOE ε4 genetic variant. The finding suggests a scalable pathway for early detection and monitoring, shifting the disease profile toward immune-driven pathology.
Healthy life expectancy hits new low in the UK
Healthy life expectancy in the UK has fallen to its lowest level since 2011, with people now expecting only 60.7 years for men and 60.9 years for women in good health—a decline of 1.8 to 2.5 years since 2019. This divergence between rising overall life expectancy and declining healthy life expectancy reflects a critical failure in prevention and upstream health determinants, not medical treatment capacity.
Modifying Role of Sustainable Diets on the Association Between Particulate Matter and Biological Aging: The Guangzhou Biobank Cohort Study
Higher PM 2.5 and PM 10 exposure accelerates biological aging markers in older adults, but adherence to plant-based dietary patterns significantly attenuates this acceleration. The protective effect is strongest in individuals with genetic predisposition to shorter lifespan.
Arvinas reports 2025 results and outlines upcoming pipeline milestones
Arvinas, a targeted protein degradation biotech firm, reported $262.6 million in full-year 2025 revenue with multiple clinical programs advancing across neurodegenerative and oncology indications. The company maintains sufficient capital funding through mid-2028 and expects data readouts from several pipeline candidates in 2026.
Structural signature of plasma proteins classifies the status of Alzheimer’s disease
Plasma protein structural changes—not just abundance—distinguish Alzheimer's disease progression and predict disease status independent of traditional genetic risk markers. This approach identifies conformational biomarkers that shift with disease stage, genotype, and sex, offering a measurable window into pathological mechanisms before cognitive decline becomes severe.
$30.8m funds Cambrian Bio’s bid to preserve resilience in aging
Cambrian Bio received $30.8 million in ARPA-H funding to test whether a selective mTORC1 inhibitor can preserve intrinsic capacity—the physical and metabolic resilience that maintains function during aging—before disease manifests. This represents a fundamental shift from treating established disease to intervening in the aging process itself, with success measured through a composite biomarker framework rather than disease endpoints.
Linnaeus wins $22m to address aging before decline
ARPA-H has awarded $22 million to Linnaeus Therapeutics to test LNS8801, an oral drug designed to preserve physical and cognitive function in aging before decline occurs. The approach represents a shift from treating age-related disease toward maintaining the integrated capacities that sustain independence and resilience.
From longevity hype to clinical rigor
Longevity medicine has entered clinical practice ahead of its evidence base, creating a gap between consumer demand and scientific rigor. Establishing clinical registries, standardized protocols, and rigorous trial infrastructure is essential for the field to transition from a commercial marketplace to a credible medical discipline.
A Metabolic Shift Fuels Stem Cell Dysfunction
Age-related hypermethylation of IGF2BP3 impairs glutathione metabolism in aging stem cells, causing loss of proliferative capacity and regenerative function. This metabolic collapse explains why autologous stem cell therapies perform poorly in older patients and identifies a specific epigenetic mechanism linking aging to cellular dysfunction.
DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment
Senolytic treatments did not reverse epigenetic signatures associated with cellular senescence, despite reducing senescent cell burden. This finding questions whether DNA methylation changes adequately capture senescence biology and whether current aging biomarkers respond as expected to geroscience interventions.
Lactose‐Derived Carbohydrates Induce Sexually Dimorphic Nutritional Programming Effects on Lifespan in Drosophila melanogaster
Early-life consumption of galactose and glucose (lactose components) extends lifespan in female flies exposed to obesogenic diets in adulthood through reprogramming of lipid metabolism, while reducing lifespan in males. This nutritional programming effect demonstrates that early dietary composition establishes metabolic resilience patterns that persist throughout life and respond differentially by sex.
Intergenerational Transmission of Metabolic Changes in Oocytes From Aged Mice
Oxidative stress in oocytes from aged female mice triggers lipid accumulation and metabolic alterations that persist through three generations, with offspring developing compensatory antioxidant responses in lipid-rich tissues. This demonstrates that maternal aging imprints metabolic dysfunction on descendants independent of direct genetic mutation.
Building a ‘Swiss Army Knife’ longevity drug
LinkGevity is developing a small-molecule therapeutic targeting necrosis—uncontrolled cell death—as an upstream driver of multiple age-related diseases. By intervening at this central physiological node, the approach aims to address degenerative change across chronic conditions simultaneously rather than treating diseases individually.
Tectonic Therapeutic names François Nader as chair and independent director
Tectonic Therapeutic appointed Dr. François Nader as board chair and independent director to strengthen governance during clinical development of targeted cancer therapies. This leadership change reflects the company's focus on strategic oversight and regulatory execution as it advances precision medicine programs.
Longeveron publishes stem cell therapy frailty trial results
Longeveron's Phase 2b trial of allogeneic mesenchymal stem cells in older adults with frailty demonstrated safety and measurable improvements in physical performance, including gait speed and functional measures. Results published in Cell Stem Cell validate a therapeutic approach targeting age-related functional decline rather than isolated disease markers.
Recursion reports 2025 financial results and outlines 2026 milestones
Recursion Pharmaceuticals reported $74.7 million in full-year 2025 revenue and delivered first clinical validation of its AI-enabled drug discovery platform in familial adenomatous polyposis. The company's pipeline advances multiple programs with near-term catalysts across immunology and oncology.
Subtyping Alzheimer’s disease and Parkinson’s disease using longitudinal electronic health records
Machine learning analysis of UK health records identifies distinct subtypes of Alzheimer's and Parkinson's disease with shared clinical patterns and divergent genetic signatures. These subtypes enable earlier detection and inform disease-specific intervention strategies, moving beyond one-size-fits-all approaches to neurodegenerative disease management.
From wrist data to lifespan: elucidating inflammation-driven biological aging via activity rhythms captured by wearable devices
Wearable devices tracking activity rhythms reveal that irregular movement patterns correlate with systemic inflammation and accelerated biological aging. This connection between circadian disruption and aging rate offers a quantifiable marker for longevity risk that precedes clinical disease.
YOU(th) lands funding for smartphone-based preventive health screening
YOU(th) has secured $4.5 million to advance a smartphone-based screening platform that analyzes facial video, voice, eye images, and movement patterns to assess over 50 digital biomarkers across multiple organ systems in under two minutes. The approach aims to reduce friction in preventive health screening by leveraging ubiquitous smartphone sensors to detect physiological and metabolic signals outside traditional clinical settings.
Smoking Linked to Lower Parkinson’s Risk but Higher Mortality
Smokers show reduced Parkinson's disease incidence, but this protective association is offset by markedly elevated overall mortality. Quitting smoking remains the only evidence-supported path to reducing total mortality risk, despite temporary increases in neurodegenerative disease incidence during the transition.
João Pedro de Magalhães on the Ethics of Longevity
João Pedro de Magalhães and Zhuang Zhuang Han have published a peer-reviewed ethical framework addressing persistent public and scientific concerns about longevity science. The paper provides researchers with evidence-informed arguments to address misconceptions about aging intervention—concerns that have remained largely consistent over two decades despite scientific progress.
ARPA-H pours millions into healthspan-focused human trials
ARPA-H is allocating $144 million through its PROSPR program to fund seven research teams testing interventions designed to extend healthspan in humans. The initiative addresses a critical gap in geroscience drug development by establishing early biomarkers and trial designs that can demonstrate functional benefit within one to three years rather than decades.
Gene editing partnership reaches new in vivo success
Scribe Therapeutics and Eli Lilly have achieved a second milestone in developing in vivo CRISPR-based therapies for neurological and neuromuscular diseases. This advances the practical application of gene editing directly within the body, potentially enabling durable treatments delivered once or rarely, rather than requiring repeated interventions over a patient's lifetime.
Syndex Bio’s mcPCR opens new path for early disease detection
Syndex Bio's mcPCR technology preserves DNA methylation patterns during amplification, enabling detection of disease-associated epigenetic changes from minimal samples. This advance addresses a critical gap in early disease detection and biological age assessment, with implications spanning oncology, prenatal diagnostics, and longevity research.
Menopausal Hormone Therapy Does Not Increase Mortality
An analysis of over 800,000 Danish women found no association between menopausal hormone therapy and increased all-cause mortality over 7-21 years of follow-up. This challenges the prevailing safety concerns that emerged from earlier studies and suggests the risk-benefit calculation for hormone therapy in perimenopausal women warrants reassessment based on individual clinical context.
Vivtex inks $2.1b Novo Nordisk collab for oral obesity drug
Novo Nordisk's $2.1 billion partnership with Vivtex aims to convert injectable obesity and diabetes medications into oral formulations, addressing a critical gap between drug efficacy and real-world adherence. The collaboration targets peptide therapeutics that are difficult to deliver orally while maintaining bioavailability, signaling that the obesity treatment landscape is shifting from efficacy metrics toward practical administration and sustained patient compliance.
The Association Between Exposure to Blue Spaces and Multidimensional Frailty in Community-Dwelling Older Adults: A Cross-Sectional Study
Proximity to and regular contact with water environments—blue spaces—correlates with reduced frailty severity in older adults across physical, cognitive, and social dimensions. This relationship suggests environmental design and accessibility may modulate age-related decline in ways comparable to conventional medical interventions.
[Articles] The impact of exercise interventions on domains of quality of life in women diagnosed with breast cancers during chemotherapy treatment: a meta-analytic review
Exercise during chemotherapy improves quality of life outcomes in breast cancer patients, with aerobic and combined aerobic-strength training demonstrating measurable benefit. This finding establishes physical activity as a modifiable factor capable of mitigating treatment-related decline across multiple functional domains.
Supportive Environmental Features at Home as Proactive/Reactive Associates of Disability and Mortality Status in Older Adults
Supportive environmental features in homes—grab bars, accessible layouts, lighting modifications—correlate with reduced disability progression and mortality risk in older adults. Implementation patterns vary significantly, and proactive installation (before functional decline) shows stronger protective associations than reactive modification after disability emerges.
Select Small Non‐Coding RNAs Are Determinants of Survival in Older Adults
Circulating small RNAs, particularly nine piRNAs, predict two-year survival in older adults with greater accuracy than age and clinical factors alone, with experimental evidence suggesting reduced piRNA levels associate with extended lifespan. These findings identify specific small RNA signatures as measurable biomarkers and potential therapeutic targets for longevity interventions.
Self- vs. Other-Focused Attention and Appearance Self-Evaluation in the Oldest-Old: Gendered Implications for Person-Centered Care
Attention direction—whether focused inward on oneself or outward toward others—significantly influences how older adults evaluate their own appearance, with differential effects by gender. This finding suggests that cognitive framing and attentional patterns shape self-perception and potentially affect psychological well-being and social engagement in aging.
The Mediating Role of Sleep Duration in the Association Between Adverse Childhood Experiences and Depressive Symptoms Among Middle-Aged and Older Chinese Adults: A Nationwide Longitudinal Study
Sleep duration mediates the relationship between adverse childhood experiences and depressive symptoms in middle-aged and older adults, suggesting that inadequate sleep represents a mechanistic pathway through which early trauma influences long-term mental health outcomes. This finding identifies a modifiable factor that may interrupt the trajectory from childhood adversity to depression in aging populations.
Silencing of the Metabolic Gene HKDC1 Is Associated With Aging and Neurodegeneration in Mice and Humans
HKDC1, a metabolic enzyme, declines with age due to chromatin remodeling that blocks its transcription factor regulation, and this decline correlates with cognitive impairment and neurodegeneration in both mice and humans. Loss of HKDC1 compromises mitochondrial integrity and triggers neuroinflammation, establishing a mechanistic link between metabolic gene silencing and age-related neurological decline.
Life Time posts strong revenue and profit growth in 2025
Life Time reported 14.3% year-over-year revenue growth to $2.99 billion in 2025, with net income rising 139.2% to $373.7 million, driven by membership expansion and increased utilization of its athletic facilities. This financial performance reflects sustained market demand for integrated fitness and wellness services.
Seveno backs PointFit wearable patch
Seveno Capital's investment in PointFit reflects a market shift toward direct biochemical monitoring via wearable patches that measure lactate and other sweat biomarkers in real time. Continuous metabolic substrate tracking—rather than behavioral proxies like step count—provides actionable insight into energy dynamics, recovery debt, and metabolic flexibility relevant to both performance optimization and early detection of metabolic decline.
OMICmAge quantifies biological age by integrating multi-omics with electronic medical records
OMICmAge integrates multi-omics data with DNA methylation to create a biological age measure that predicts disease and mortality risk more accurately than chronological age alone. This approach enables risk stratification based on measurable molecular signatures rather than calendar years.
Hertility announced as Women’s Health Partner for Longevity Show
Hertility has been named Scientific Lead Partner for the Women's Health Summit at the 2026 Longevity Show, positioning female biology as a structural framework—not peripheral content—for longevity science. The partnership addresses a fundamental data gap: longevity research has been calibrated to male physiology, requiring sex-specific diagnostic infrastructure and longitudinal data to advance clinical outcomes.
Klothea initiates longevity-focused human trial of klotho therapy
Klothea Bio has initiated a Phase 1b trial of AKL003, an mRNA therapy designed to elevate circulating alpha klotho protein levels in healthy adults. The trial represents a direct approach to testing whether increased klotho—a protein associated with organ protection and repair across multiple physiological systems—can favorably shift biomarkers linked to human lifespan and biological age.
Nanoplastics found in the brain raise new aging questions
Nanoplastics have been detected in human brain tissue and show correlation with neurodegenerative disease severity and accelerated aging markers. The particles' ability to cross biological barriers and interact with pathological proteins suggests chronic, low-level exposure represents a longevity risk distinct from acute toxicity.
Thermogeneration by White Fat Could Be Used to Treat Obesity
White adipocytes possess an FFA-driven uncoupling mechanism independent of UCP1 that dissipates energy as heat through the AAC protein. This pathway represents a targetable mechanism for therapeutic intervention in obesity and metabolic dysfunction.
FDA rewrites drug approval rules and longevity stands to gain
The FDA has shifted its drug approval standard from requiring two pivotal clinical trials to accepting one, citing advances in biological understanding, biomarker validation, and trial design sophistication. This regulatory change has direct implications for aging-related therapeutics, where slow biological processes and prevention-focused interventions have historically faced approval barriers under the two-trial requirement.
Antiaging shifts upstream as cell wellness gains traction
The personal care and longevity industry is shifting from treating visible signs of aging to supporting cellular health upstream, positioning products as maintenance tools for biological function rather than cosmetic fixes. This repositioning extends the customer lifecycle while aligning consumer expectations with the biological mechanisms of aging.
Correction to “Spatial Reorganization of Chromatin Architecture Shapes the Expression Phenotype of Therapy‐Induced Senescent Cells”
This correction addresses a published study on how senescent cells reorganize their chromatin architecture in response to therapeutic stress. Understanding the structural changes in non-dividing cells has direct implications for improving cellular resilience and longevity through better therapeutic design.
Senescence at the crossroads of postpartum remodeling and tumorigenesis
Cellular senescence plays a dual role in postpartum mammary gland remodeling—supporting normal tissue reorganization while simultaneously creating conditions that enhance tumor progression when oncogenic events coincide with gland involution. This mechanism reveals how a normally protective cellular state becomes pathogenic under specific developmental and genetic circumstances.
Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling
Proteomic analysis identifies distinct and overlapping protein signatures across different manifestations of cerebral small-vessel disease, revealing shared involvement of vascular, immune, and neuronal pathways. Plasma protein panels show predictive capacity for cerebrovascular events, establishing measurable biomarkers for disease stratification and risk assessment.
How a Sirtuin Protects Against Brain Diseases
SIRT6, a sirtuin protein, protects against neurodegenerative diseases by maintaining nucleolar function and constraining protein synthesis, preventing the accumulation of misfolded proteins that drives age-related brain pathology. This mechanism represents a direct intervention point in proteostasis failure, a primary driver of cognitive decline.
Longevity Show launches 2026 pitch competition
The Longevity Show launches a 2026 pitch competition for consumer-ready healthspan startups, targeting the critical gap between laboratory discovery and real-world implementation. The competition emphasizes clinical plausibility and measurable impact over marketing hype, reflecting the sector's maturation toward systems-based, scalable prevention rather than isolated interventions.
Scienta’s new AI model targets aging-linked inflammation
Scienta Lab's EVA, a multimodal AI model, accelerates drug discovery for inflammation-related diseases by integrating gene activity, tissue, and protein data to predict clinical outcomes before human trials. For longevity medicine, this tool addresses inflammaging—the chronic, low-grade inflammation driving age-related diseases—potentially compressing drug development timelines from decades to years.
AI’s role in the next era of longevity biotech
Artificial intelligence is compressing drug discovery timelines from four to five years to approximately fourteen months by automating target identification, molecular design, and clinical trial prediction. This acceleration has direct implications for longevity therapeutics, where speed to market can determine whether interventions reach patients before age-related decline progresses beyond intervention points.
CSPC’s monthly weight-loss shot advances to US trials
CSPC Pharmaceutical's SYH2082, a once-monthly GLP-1/GIP receptor agonist, has received FDA approval to begin US clinical trials. The extended dosing interval addresses a critical barrier to treatment adherence that weekly alternatives have not solved, with potential implications for sustainable weight management and metabolic disease prevention.
Could Ginkgo’s OpenAI collab accelerate progress in longevity?
An autonomous laboratory system combining GPT-5 reasoning with Ginkgo's cloud infrastructure executed over 36,000 cell-free protein synthesis experiments in six months, reducing production costs by 40% while maintaining experimental rigor. This approach addresses a primary constraint in longevity research: the ability to test sufficient hypotheses at scale and speed without proportional increases in cost and human labor.
Serina Therapeutics enrolls first patient in Parkinson’s trial
Serina Therapeutics has initiated a Phase 1b trial of SER-252, a subcutaneous apomorphine delivery system designed to maintain therapeutic drug levels in advanced Parkinson's patients with inadequate symptom control. The approach addresses motor fluctuations by extending the duration of dopaminergic exposure, a limitation of current standard therapies.
Pathways to Falls Among Community-Dwelling Older Women: The Mediating Role of Cognitive Decline and Fear of Falling
Fear of falling and cognitive decline act as mediating pathways linking physical and psychological risk factors to fall incidence in older women living in community settings. This identifies actionable intervention points beyond treating isolated fall risk factors.
Entropy of Muscle Fiber Histology Predicts Mobility in Older Adults: The Study of Muscle, Mobility, and Aging
Muscle fiber disorganization, quantified as a homeostatic dysregulation index, independently predicts mobility decline and reduced mitochondrial function in adults over 70, regardless of muscle mass. This establishes structural entropy as a measurable mechanism of skeletal muscle aging separate from loss of size alone.
Ageing Through the Looking‐Glass: The Different Flavours of Clonal Haematopoiesis
Clonal haematopoiesis reflects genomic instability with aging and links to malignancy, cardiovascular disease, and age-related conditions. Multiple forms of CH share common risk factors and may amplify inflammatory and immune dysfunction, offering insight into how cellular mutations drive aging-related pathology.
Attenuating age-related decline in dendritic cell migration improves vaccine efficacy via gut-immune crosstalk
Dendritic cell migration from the gut declines with age, impairing vaccine response. Oral delivery of yeast-derived nanoparticles restores this migration pathway and vaccine efficacy in aged mice, pointing to a specific mechanism by which immune function deteriorates and can be supported.
WELL Health and HEALWELL AI launch consent‑first research platform
WELL Health and HEALWELL AI launched WELLTRUST, a consent-first platform that uses AI-driven patient matching to accelerate clinical trial recruitment while preserving privacy and patient autonomy. The system connects outpatient clinic networks with advanced matching algorithms to identify eligible participants for research on chronic, rare, and complex conditions at scale.
Lario Therapeutics wins $2.4M funding to advance CNS drug platform
Lario Therapeutics received $2.4 million in funding to advance a neuronal calcium channel platform targeting central nervous system disorders, particularly Parkinson's disease. The investment supports preclinical development of Cav1.3 channel modulators with potential application across multiple neurodegenerative conditions.
Novos trial shows cardiovascular benefits in aging adults
A Novos clinical trial demonstrated statistically significant reductions in systolic and diastolic blood pressure, improved lipid profiles, and favorable shifts in metabolic markers among adults over 40 following the company's integrated lifestyle and metabolic support program. These findings support multimodal intervention as an approach to reducing established cardiovascular risk factors associated with aging.
Calquence combination gains US approval for first-line CLL treatment
The FDA approved Calquence plus venetoclax as the first all-oral, fixed-duration first-line treatment for chronic lymphocytic leukemia, delivered over 14 months with potential for treatment-free intervals afterward. This chemotherapy-free combination demonstrated improved progression-free survival compared to standard chemoimmunotherapy and represents a shift toward targeted therapies that address specific disease pathways.
Epigenetic Clocks of Biological Aging and Risk of Incident Mild Cognitive Impairment and Dementia: The Women's Health Initiative Memory Study
Accelerated biological aging measured by the epigenetic clock AgeAccelGrim2 was associated with increased risk of mild cognitive impairment and dementia in 6,069 cognitively unimpaired women over 9.3 years of follow-up, independent of chronological age. This establishes epigenetic markers as measurable indicators of neurodegeneration risk.
Acceleration of Lactate Uptake and Utilization Contributes to Neuroprotective Action of FGF21 Involved in Naturally Aging Mice
FGF21 enhances lactate uptake and utilization in the aging brain, protecting against neuroinflammation-driven cognitive decline. This mechanism reveals how metabolic efficiency at the cellular level directly influences neuronal resilience during aging.
GLP-1 drugs fail to slow cognitive decline in Alzheimer’s disease
Recent evidence indicates GLP-1 receptor agonists do not slow cognitive decline in established Alzheimer's disease, despite theoretical mechanistic rationale and their known metabolic benefits. This finding redirects focus toward earlier intervention windows and prevention strategies rather than disease reversal in advanced stages.
Sleep Duration and Chronic Disease Risk in Later Life: Longitudinal Evidence and Mechanism Analysis From China
Both short and long sleep duration independently increase chronic disease risk in older adults, with sleep duration showing a dose-response relationship to multimorbidity. The effect operates through metabolic dysregulation, inflammatory pathways, and autonomic nervous system dysfunction rather than a single mechanism.
Analyzing Age-Specific Contributions to Life Expectancy Gains Across Europe
Life expectancy gains across Europe result from mortality improvements distributed across different age groups, with patterns varying significantly by country and time period. Understanding these age-specific contributions reveals where public health interventions have been most effective and where future efforts should focus.
Issue Information
I cannot access external URLs or retrieve article content beyond what you provide. The excerpt you've shared contains only publication metadata (journal name, volume, issue, date) without substantive research findings. Please provide the full article text or abstract so I can deliver the analysis you've requested.
Unraveling the role of polyamine metabolism in postoperative delirium: insights into biochemical mechanisms and biomarker potential
Polyamine metabolism dysregulation emerges as a mechanistic contributor to postoperative delirium, with specific metabolites showing potential as predictive biomarkers. This work identifies a biochemical pathway relevant to acute cognitive dysfunction in aging populations and surgical contexts, offering a measurable entry point for intervention.
Antioxidant vitamin index and risk of age-related macular degeneration: multicenter validation and clinical translation
A multicenter validation study establishes a quantifiable antioxidant vitamin index that predicts age-related macular degeneration risk, enabling clinicians to stratify patients and intervene with targeted nutritional strategies before vision loss occurs.
L-Nutra named Innovator Partner for the Longevity Show 2026
L-Nutra's fasting-mimicking technology platform, validated across 47 clinical trials and 18 university research centers, repositions precision nutrition as essential healthcare infrastructure rather than lifestyle optimization. The company's approach uses targeted nutrient formulations to trigger cellular repair mechanisms—autophagy and metabolic signaling—without the physiological stress of extended fasting, addressing metabolic dysfunction and age-related chronic disease at a systems level.
What happens when longevity education moves into the clinic?
Structured education in longevity medicine measurably shifts physician confidence and clinical behavior across 42 countries. This represents the first empirical evidence that teaching evidence-based aging biology translates into actionable changes in routine medical practice—closing a significant gap between longevity science and clinical delivery.
Korsana emerges with $175m to combat neurodegenerative diseases
Korsana Biosciences has secured $175 million to develop KRSA-028, a monoclonal antibody for Alzheimer's disease that uses transferrin receptor-based shuttle technology to cross the blood-brain barrier more effectively than existing therapies. The approach addresses a fundamental delivery limitation in treating neurodegenerative diseases, with Phase 1 data expected in mid-2027.
Microsensor for glucose monitoring hits world-first 10-day milestone
Sava Technologies has demonstrated a minimally invasive microsensor that continuously monitors glucose for 10 days with accuracy comparable to traditional continuous glucose monitors, while requiring a filament roughly 10 times shorter and causing substantially less tissue disruption. This advance addresses a critical adoption barrier in glucose monitoring, where discomfort and skin irritation have limited consistent use despite established clinical benefits.
AI Tool Sets New Standard in Diagnosing Rare Diseases
DeepRare, a multi-agent AI system combining large language models with specialized diagnostic tools, demonstrated superior performance in identifying rare diseases compared to other digital tools and human physicians. The system addresses a critical clinical problem: patients with rare diseases wait an average of 5+ years for diagnosis, enduring repeated misdiagnoses and unnecessary interventions.
ALS drug PrimeC cuts death risk by 65%
Long-term follow-up data from NeuroSense's PrimeC trial in ALS patients demonstrates a 65% reduction in death risk and median survival extension of 14+ months—a magnitude rarely achieved in neurodegenerative disease. This represents a potential shift from symptomatic management toward disease modification in a rapidly progressive condition.
Pancreatic cancer competitive landscape shows broad innovation
Over 180 companies are developing 190+ drug candidates across multiple therapeutic classes for pancreatic cancer, spanning early to late clinical stages. This pipeline activity reflects sustained industry effort to address one of oncology's most intractable diseases, though clinical translation remains challenging.
Sickle cell disease competitive landscape highlights broad drug pipeline
Over 40 companies are developing more than 50 drug candidates for sickle cell disease across gene therapy, gene editing, and small molecule approaches, with several candidates in late-stage clinical trials. This expansion of therapeutic options addresses a genetic blood disorder that directly compromises oxygen delivery, energy production, and tissue regeneration—core drivers of age-related pathology.
ALS therapeutics landscape projects growth through 2035
The global ALS therapeutics market is projected to more than double from $812 million in 2024 to $1.964 billion by 2035, driven by innovation in disease-modifying and neuroprotective approaches including antisense oligonucleotides, gene therapies, and biologics. This expansion reflects a fundamental shift in treatment philosophy from symptomatic management toward interventions that address underlying neurodegeneration.
Human Longevity launches personal AI‑powered longevity app
Human Longevity has released an AI-powered mobile app that analyzes biometric, lifestyle, and genetic data to generate personalized health recommendations across nutrition, exercise, sleep, and preventive care. The platform's utility depends on the quality of data interpretation and user adherence to recommendations over time.
Immortal Dragons backs 3D biofabrication to tackle organ failure
Immortal Dragons is directing capital toward 3D biofabrication technologies that use living cells and biocompatible materials to engineer functional tissues and vascular structures. This represents a strategic shift in longevity investment toward regenerative approaches that intervene before organ failure becomes clinically symptomatic.
Seeing the Mind: Associations Between Distance and Near Vision Impairment and Cognitive Performance Among Community-Dwelling Older Adults
Visual impairment in older adults—both distance and near vision—correlates with measurable cognitive decline independent of age and education. The association suggests vision loss creates a bidirectional relationship with cognitive performance, making visual function a potentially modifiable risk factor in cognitive aging.
Fallopian tube cancer market growth driven by targeted therapies
This article reports on pharmaceutical market expansion in fallopian tube cancer treatment through targeted therapies and companion diagnostics, driven by improved genetic testing for BRCA1/BRCA2 mutations and earlier detection. The development of biomarker-driven, personalized approaches addresses a rare gynecologic malignancy where prevention and early intervention now have clinical pathways.
Are levels of DHEAS indicative of subjective health – results of the population-based longitudinal CARLA study
Dehydroepiandrosterone sulfate (DHEAS) levels correlate with subjective health perception in a longitudinal population study, suggesting this adrenal steroid may serve as a physiological marker for how individuals experience their own health status. The finding bridges objective biochemistry with subjective well-being, relevant to understanding which biomarkers meaningfully predict health experience across the lifespan.
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease
Risvodetinib, a c-Abl kinase inhibitor, demonstrated safety and tolerability in a 12-week phase 2a trial of patients with early untreated Parkinson's disease. This represents preliminary evidence for a mechanistic approach to slowing neurodegeneration in the disease's presymptomatic window.
Lario gets $2.4m to push brain-targeted drugs further
Lario Therapeutics secured $2.4 million in grant funding to advance precision neuronal calcium channel therapies for Parkinson's disease and PTSD. The approach targets specific ion channels implicated by human genetics rather than broadly suppressing neural activity, representing a shift toward mechanism-based drug development for neurodegenerative and psychiatric disorders.
AI-driven food app targets disease prevention and aging
Foodhak uses AI-driven personalization to translate nutrition science into daily food guidance aligned with individual health markers and goals. The approach positions food as preventive medicine rather than caloric constraint, addressing a systemic gap where most food choices optimize for taste and cost rather than long-term health outcomes.
Clair Health launches wearable hormone intelligence
Clair Health has launched a non-invasive wearable that uses multimodal biosensors and AI to infer continuous hormonal patterns across the female lifespan, moving beyond episodic blood tests and calendar-based tracking. The device collects skin temperature, heart rate variability, sleep, and breathing data as proxies for endocrine state, positioning hormonal monitoring as a prevention tool rather than a fertility marker.
A Circulating Inflammation Suppressor Decreases Mortality
Mendelian randomization analysis demonstrates that elevated IL-6, a pro-inflammatory cytokine, causally increases mortality risk, while circulating IL-6 receptor (IL6R) decreases it. This identifies a specific inflammatory pathway amenable to therapeutic intervention in age-related mortality.
Unnatural Products inks $1.7b cardiovascular disease collab with Novartis
Unnatural Products and Novartis have partnered to develop macrocyclic peptides—molecular structures between small molecules and biologics—targeting protein interactions implicated in cardiovascular disease and age-related conditions. This approach addresses a critical gap in drug development where conventional therapeutics cannot effectively engage disease-driving targets.
Why aging feels harder after 40
Circulating stem cell count declines sharply after age 30, reducing tissue repair capacity and resilience. This decline correlates with recovery time, injury healing, and disease risk—making stem cell abundance a measurable predictor of healthspan independent of conventional longevity markers.
Longevity market poised for growth as AI and genomics accelerate developments
The global longevity market is projected to exceed $740 billion by 2026, driven by a structural shift toward integrated healthcare platforms combining AI, genomics, and regenerative medicine. This transition reflects movement from consumer wellness toward clinical prevention and early risk detection supported by institutional stakeholders.
Sana Biotechnology appoints Brian Piper as CFO
Sana Biotechnology appointed Brian Piper as CFO to strengthen financial leadership during advancement of its cell and gene therapy pipeline. This personnel move signals the company's commitment to clinical-stage programs targeting cancer and neurological disorders, positioning it for potential regulatory and commercial milestones.
Theriva Biologics licenses SYN‑020 to Rasayana Therapeutics
Theriva Biologics has licensed SYN-020, an orally delivered recombinant intestinal alkaline phosphatase, to Rasayana Therapeutics for development across metabolic and inflammatory disorders. The therapy targets intestinal barrier function and microbiome health—mechanisms directly relevant to age-related disease prevention and metabolic dysfunction.
NeuroSense reports significant survival benefit with PrimeC in ALS trial
PrimeC, a combination of two FDA-approved drugs in extended-release formulation, demonstrated a 14.7-month median survival improvement in ALS patients (36.3 months versus 21.4 months with placebo), with a 65% reduction in mortality risk after adjustment for baseline factors. This represents a clinically meaningful survival benefit in a neurodegenerative disease with limited therapeutic options.
EyePoint names Michael Campbell as chief commercial officer
EyePoint Pharmaceuticals appointed Michael Campbell as Chief Commercial Officer to lead commercial strategy for DURAVYU, an investigational intravitreal insert for wet age-related macular degeneration and diabetic macular edema in Phase 3 development. This appointment signals preparation for potential market entry following anticipated pivotal data readouts in mid-2026.
Maze Therapeutics teams with Zifo to enhance precision medicine data tools
Maze Therapeutics and Zifo Technologies are partnering to streamline analysis of large biobank datasets using AI-enabled informatics, enabling faster translation of genetic data into validated drug targets. This infrastructure advancement reduces technical barriers in precision medicine research and accelerates the identification of therapeutically relevant genetic signals.
GenSight Biologics expands regulatory leadership in US and Europe
GenSight Biologics appointed two senior regulatory officers to lead global drug development strategy as the company advances gene therapies for retinal and central nervous system disorders. The leadership expansion supports progression through regulatory milestones and expanded clinical activity across major markets.
Scribe Therapeutics reaches second milestone in Lilly collaboration
Scribe Therapeutics and Eli Lilly have achieved a second development milestone in their partnership to create in vivo CRISPR-based genetic medicines for neurological and neuromuscular diseases. The progress validates their X-Editor platform and data-driven optimization approach for precise gene editing, positioning these therapies to address conditions with limited treatment options.
Visceral adiposity, metabolic health and aging
Visceral adipose tissue accumulation in midlife correlates with metabolic dysfunction, but the relationship is contextual rather than categorical. The review identifies conditions under which visceral fat becomes pathogenic and describes interventions to mitigate harm.
Short lifespan under dietary cholesterol depletion is associated with gut dysfunction in Drosophila melanogaster females
Dietary cholesterol depletion shortens lifespan in female fruit flies through mechanisms linked to intestinal barrier dysfunction and altered microbial composition. The finding suggests cholesterol's structural and signaling roles in gut integrity are essential for longevity, independent of cardiovascular effects typically associated with cholesterol restriction.
Menopause linked to brain structure shifts
Post-menopausal women show measurable reductions in gray matter volume within memory and emotion-regulating brain regions, correlating with increased anxiety, depression, and sleep disruption. This structural shift represents a neuroendocrine transition point with downstream implications for cognitive resilience and cardiometabolic risk in aging.
Lifetime Cognitive Enrichment Associated With Less Dementia
Lifetime cognitive enrichment from childhood through late life is associated with a 38% reduced dementia risk and delays cognitive decline by 5–7 years. The protective effect accumulates across all life stages, with late-life engagement showing the strongest individual contribution to risk reduction.
Global Conference to Tackle Longevity Clinical Translation
The NUS Academy for Healthy Longevity is hosting a Geromedicine Conference in February 2026 to advance the clinical translation of geroscience research into practical interventions. The event will focus on implementing evidence-based strategies including targeted molecules, bioactive compounds, and repurposed pharmaceuticals within personalized care frameworks.
Could PGC-1α hold the key to longevity?
PGC-1α, a transcriptional coactivator that regulates cellular energy metabolism and mitochondrial biogenesis, is emerging as a target for age-related disease intervention. Endurance Bio is advancing a small molecule (T-168) designed to upregulate PGC-1α, with Phase 2 trials underway in Parkinson's disease and potential applications across neurodegeneration, metabolic dysfunction, and frailty.
Listening to biology’s early whispers
Chronic diseases develop through years of subtle, cumulative molecular drift before clinical diagnosis. The Buck Institute proposes longitudinal, AI-driven monitoring against individual baselines—treating each person as their own biological reference—to detect these early deviations rather than waiting for symptomatic presentation.
Serotonin Anti-Aging Centers signs multi-location expansion deal in North Texas
Serotonin Anti-Aging Centers is expanding its hormone optimization and longevity clinic network with five new locations in North Texas. The expansion reflects growing consumer demand for personalized preventive health and age-management medicine delivered through standardized clinical protocols.
Your gut microbes can be anti-aging – scientists are uncovering how to keep your microbiome youthful
Gut microbiome composition predicts biological age and directly influences aging trajectories. Maintaining microbial diversity through dietary fiber and exercise represents a measurable pathway to extend healthspan, with fiber supplementation associated with 20–37% improvements in healthy aging outcomes.
[Personal View] Responsible use of artificial intelligence in the provision of long-term care for older people: a care-centric approach
AI implementation in long-term care for older people risks compromising care quality when framed narrowly around workforce efficiency rather than centered on care outcomes and ethical implications. A care-centric approach requires understanding how automation affects the complex relational and systemic structures that support health across the lifespan.
Are global brands ready for longevity?
Edelman's longevity report demonstrates that global brands underinvest in the 55+ demographic despite this group controlling over half of global spending and showing higher brand loyalty than younger consumers. Misaligned business models that assume peak value at midlife cost economies hundreds of billions annually and represent a significant missed opportunity for sustained revenue and relationship building.
Development and Testing of the Social Connection in Long-Term Care Home Residents (SONNET) Scale
Researchers developed and validated the SONNET Scale, a measurement tool for assessing social connection among long-term care residents. Social isolation in institutional settings is a documented risk factor for accelerated decline in cognition, immune function, and overall mortality—making reliable measurement the prerequisite for intervention.
Recommendations for How Employers Can Support Family Caregivers: Results From an Expert Delphi Consensus Panel
Employed family caregivers experience significant strain that affects both workplace performance and personal health outcomes. Organizational support structures—including flexible scheduling, paid leave, and access to caregiver resources—reduce this burden and improve retention while supporting the health resilience of the caregiver population.
SIRT6 Regulates Protein Synthesis and Folding Through Nucleolar Remodeling
SIRT6 maintains proteostasis by suppressing ribosomal gene expression and translation rates through nucleolar control. Without functional SIRT6, excessive protein synthesis overwhelms the folding machinery, leading to protein aggregation and accelerated neurodegeneration in aging models.
Oligonucleotide therapeutics market forecast to reach $17.7B by 2030
The oligonucleotide therapeutics market is projected to reach $17.7 billion by 2030, growing at 19.7 percent annually from 2025. Advances in RNA-targeting medicines and delivery technologies are enabling precision approaches to neurological disorders and rare diseases where conventional pharmaceuticals have limited efficacy.
Harness Therapeutics nominates HRN001 for Huntington’s disease
Harness Therapeutics has nominated HRN001, a protein upregulation therapy targeting the DNA repair protein FAN1, as a candidate for Huntington's disease. The approach addresses underlying disease mechanisms by controlling somatic DNA repeat expansion rather than managing symptoms alone, with clinical development planned to follow preclinical studies.
Induction of senescence during postpartum mammary gland involution supports tissue remodeling and promotes postpartum tumorigenesis
Senescent cells drive postpartum mammary gland involution and tissue remodeling, but simultaneously create a microenvironment permissive to tumor initiation. This reveals how a tissue repair mechanism can paradoxically increase cancer risk during a critical metabolic transition.
Molecular insight into transcriptome profiling of aerobic exercise induced changes in aged skeletal muscle
Aerobic exercise induces measurable transcriptome changes in aged skeletal muscle, activating pathways associated with mitochondrial function, protein synthesis, and cellular stress resilience. These molecular shifts provide a mechanistic explanation for how structured movement preserves muscle quality and metabolic capacity across the lifespan.
The shift from stem cells to signals
Clinical evidence shows transplanted stem cells often fail to survive beyond days, yet patients continue improving—suggesting the therapeutic mechanism resides in transient molecular signals rather than cell persistence. This shift from cellular replacement to signal-based regenerative therapy reframes aging as a coordination failure rather than a structural deficit, with profound implications for scalable longevity medicine.
Edited islet cells persist for a year without immunosuppression
Sana Biotechnology's hypoimmune islet cell transplants achieved one-year persistence and function in a Type 1 diabetes patient without systemic immunosuppression, validating a cell-engineering approach that modifies transplanted cells rather than suppressing the immune system. This durability milestone suggests scalable, off-the-shelf cell therapies may be feasible without the toxicity burden of traditional immunosuppression.
What Gimv’s biotech pullback says about aging markets
Belgium's investment firm Gimv is ceasing new life sciences investments despite co-leading a $59 million funding round for an Alzheimer's biotech company, signaling a structural mismatch between venture-style biotech timelines and private equity's operational focus rather than a loss of confidence in longevity innovation.
As obesity drugs go oral and access grows, so do fakes
The transition from injectable GLP-1 drugs to oral formulations is expanding patient access and treatment options, but creates new vulnerabilities to counterfeit products that pose direct safety risks. Regulatory vigilance and supply chain authentication will be critical as the weight-loss drug market scales to an estimated $100 billion by 2030.
New Study Calculates Lifespan Gains From Five Popular Diets
A study of 103,649 UK Biobank participants found that adherence to five evidence-based dietary patterns was associated with 1.5 to 3 years of additional life expectancy, with the Diabetes Risk Reduction Diet showing the strongest association (24% lower mortality in top vs. bottom quintile). Dietary fiber and low glycemic index emerged as the most protective components, while sugar-sweetened beverages showed the strongest detrimental effect.
New functional brain assessment system rolls out in the US
QuantalX Neuroscience has launched Delphi MD, an FDA-cleared non-invasive system that quantifies real-time functional brain network activity using transcranial magnetic stimulation, electroencephalography, and AI analytics. This technology enables clinicians to detect subtle changes in brain function before structural damage or cognitive decline becomes apparent, shifting neurological care from reactive symptom management to preventive assessment.
Social Determinants of Health and Research Participation Among People Living With Mild Cognitive Impairment and Dementia
Older adults and individuals with cognitive impairment from lower socioeconomic backgrounds remain significantly underrepresented in dementia research, limiting the generalizability of findings and slowing therapeutic development for populations at highest risk. Addressing barriers to research participation directly affects whether treatments will be validated in the populations that need them most.
Association Between Future Self-Continuity and Older Adults’ Acceptance of Camera-Based Active and Assisted Living Technologies
Older adults' acceptance of camera-based monitoring technologies correlates with their sense of continuity between present and future self. Those who perceive themselves as continuous across time show greater willingness to adopt these systems, suggesting that identity and temporal perspective influence technology adoption in aging populations.
Dynamin‐Related Protein 1‐Dependent Disruption of Mitochondrial Homeostasis Drives Blue Light‐Induced Epithelial‐Mesenchymal Transition in Retinal Aging
Blue light exposure triggers excessive mitochondrial fragmentation in retinal cells through a specific protein (Drp1), driving cellular changes associated with age-related macular degeneration. Blocking this fragmentation restores mitochondrial function and reverses the pathological transformation in both cell cultures and animal models.
Association between repeated antibiotic prescribing and seizure- and other neuropsychiatric disorders-related hospitalization among people living with dementia: a population-based cohort study
Repeated antibiotic use in dementia patients correlates with increased hospitalization risk for seizures and neuropsychiatric disorders. This association suggests antibiotic exposure may alter gut microbial composition in ways that compromise neurological stability, particularly in cognitively vulnerable populations.
Silencing Growth Hormone Has Strong Effects in Mouse Brains
Suppressing growth hormone signaling in adipose tissue of aged mice preserved cognitive function, reduced neuroinflammation and cellular senescence, and restored neural firing patterns to near-youthful levels. This demonstrates adipose tissue as a peripheral regulator of brain aging independent of systemic growth hormone levels.
Aging enters the Parkinson’s lab
Preclinical Parkinson's research has relied on young animal models and acute toxin paradigms that fail to capture the disease's age-dependent biology. The PD-AGE roadmap calls for aging-integrated models—using genetic systems with gradual phenotypes and crossing them with accelerated aging strains—to better reflect how Parkinson's actually develops in older humans and improve translational reliability.
Startup builds on ‘breakthrough’ discovery to combat ALS
Vesalic has identified a systemic metabolic dysfunction originating outside the brain that drives ALS pathology through circulating exosomes carrying toxic cargo to motor neurons. This reframes ALS as a systemic disease rather than a purely CNS disorder, redirecting therapeutic strategy away from decades of brain-focused approaches with limited success.
Juvenescence expands into Abu Dhabi
Juvenescence has established operations in Abu Dhabi with access to large-scale genomic data and population health infrastructure, positioning AI-driven drug discovery within a national healthcare system oriented toward prevention and precision medicine. This move represents a strategic alignment of computational capability with national-scale assets—a model increasingly central to translating geroscience research into clinical outcomes.
Nautilus expands single-molecule proteomics into Parkinson’s
A $1.6 million collaboration between Nautilus Biotechnology, Weill Cornell Medicine–Qatar, and The Michael J Fox Foundation aims to detect alpha-synuclein proteoforms at single-molecule resolution to enable earlier Parkinson's disease diagnosis and subtype distinction. Current protein measurement tools average signals across millions of molecules, obscuring the structural variants that may drive disease progression and therapeutic response differently across individuals.
Biotech ingredient promises clinic-level skin tightening results
DermCeutical EDL, a biotech-engineered ingredient, stimulates fibroblasts to increase elastin production and reduce cellular stress, delivering measurable improvements in skin firmness and fine lines comparable to professional treatments. The development represents a shift toward topical interventions that support cellular function and dermal resilience as part of broader aging resilience.
[Articles] Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial
Hypofractionated split-course radiotherapy (HSC-RT) did not improve locoregional response compared to standard fractionated radiotherapy (SF-RT) in frail older patients with head and neck cancer, and showed inferior survival outcomes. HSC-RT may serve as a limited option only for patients unable to tolerate standard treatment after formal geriatric assessment.
HCW Biologics and WY Biotech close Trimmune financing round
HCW Biologics and WY Biotech closed financing for Trimmune, a joint venture developing immunotherapy candidates using HCW Biologics' proprietary TRBC platform. The initial funding enables advancement of HCW11-006, an oncology molecule, toward clinical trials expected to begin in China in 2027.
Biological age and immunosenescence in Colombian centenarians
Colombian centenarians show delayed immunosenescence and younger biological age despite chronological longevity, suggesting that immune system resilience rather than mere longevity is the critical predictor of healthspan. This finding reframes centenarian research toward understanding which mechanisms preserve immune function across decades.
Additional Cover
Fasting activates mitochondrial and endothelial repair mechanisms that reverse markers of vascular aging, with implications for extending healthspan through metabolic intervention. The research demonstrates that structured fasting protocols can restore cellular energy production and vascular function independent of weight loss.
Additional Cover
This research maps transcriptomic changes across multiple organs during aging in mice, revealing organ-specific and shared molecular signatures of senescence. Understanding these distinct aging patterns across tissues is fundamental to identifying intervention points for age-related decline.
Featured Cover
Astronauts exposed to spaceflight show accelerated epigenetic aging markers during mission, with partial recovery after return to Earth. This natural experiment reveals how extreme environmental stress—microgravity, radiation, isolation—affects the molecular clock and provides insight into aging acceleration mechanisms relevant to terrestrial health conditions.
Breztri shows improved outcomes in Phase III asthma trials
AstraZeneca's Phase III trials demonstrate that Breztri Aerosphere, a triple-combination inhaler, improves lung function and reduces severe asthma exacerbations compared to dual-therapy inhalers in patients with uncontrolled asthma. The therapy shows clinically meaningful gains in forced expiratory volume and exacerbation rates without new safety signals.
Alnylam reports strong 2025 revenue growth and profitability
This article reports Alnylam Pharmaceuticals' 2025 financial performance—$2.987 billion in annual revenue with 81% year-over-year growth and achievement of profitability. The financial success reflects commercial adoption of RNA interference therapeutics for rare genetic and cardiometabolic diseases, which has direct relevance to the development and accessibility of precision therapies that address underlying genetic drivers of age-related conditions.
Serotonin Centers enters Chicago market with Naperville opening
Serotonin Centers opened its first Illinois location in Naperville, offering physician-led hormone optimization, medical weight management, and aesthetic services within a concierge model. The expansion reflects growing demand for medically supervised longevity and preventive health services in major metropolitan markets.
The HIF‐1α Pathway Regulates Satellite Cell Fate During Aging Through Histone Lactylation
Pharmacological reactivation of HIF-1α signaling in aged satellite cells restores lactate-driven epigenetic remodeling and shifts cells from senescence toward a regenerative state, with treated cells demonstrating enhanced myogenic capacity and increased ATP production. This identifies a metabolic-epigenetic axis relevant to age-related muscle decline and suggests a therapeutic target for sarcopenia.
MicroRNA profiles in plasma-derived extracellular vesicles across the human lifespan
Plasma extracellular vesicles carrying microRNAs show age-specific expression patterns that correlate with biological aging across the human lifespan. These circulating biomarkers may serve as measurable indicators of systemic aging processes and inform stratification of longevity risk.
[Articles] The effects of daily low-dose aspirin on white matter hyperintensity lesions and retinal vascular calibre in healthy older adults: the ENVIS-ion exploratory neuroimaging substudy of the ASPREE randomised clinical trial
Three years of daily low-dose aspirin in healthy older adults did not reduce white matter hyperintensity progression or alter retinal vascular caliber. This finding challenges the assumption that antiplatelet therapy prevents age-related cerebrovascular changes in asymptomatic populations.
Longevity Innovation Forum in San Diego
The inaugural Longevity Innovation Forum, held March 11–12, 2026 in San Diego, convenes leading researchers, clinicians, biotech founders, and investors to advance the science and clinical translation of healthy aging. The event addresses biomarkers of longevity, epigenetic clocks, cellular rejuvenation, and strategies to modulate biological drivers of aging across multiple research domains.
Cellular Reprogramming Rescues Memory-Encoding Neurons
Partial cellular reprogramming using three Yamanaka factors (OSK) successfully restored memory function in aged mice and Alzheimer's disease models by rejuvenating memory-encoding neurons while preserving their neuronal identity. This approach demonstrates that targeted reprogramming of engram cells can reverse age-related cognitive decline without causing dedifferentiation or memory loss.
Bone signals may precede cartilage loss in osteoarthritis
Spatial proteomics reveals molecular damage signatures in subchondral bone preceding visible cartilage loss in osteoarthritis, suggesting the disease initiates as a coordinated whole-joint process rather than unidirectional cartilage erosion. Early detection at the molecular level could enable intervention before structural collapse occurs, directly impacting mobility preservation and healthspan.
Singapore convenes clinical longevity leaders
The NUS Geromedicine Conference (February 2026) addresses the translation gap between geroscience mechanisms and clinical application, bringing together researchers, clinicians, and industry to move from pathway discovery to actionable protocols in real-world longevity practice.
Longevity.Technology unveils DLT – the intelligence platform for longevity
Longevity.Technology launched DLT, an AI-driven intelligence platform that aggregates data on over 600 longevity biotech companies, clinical assets, intellectual property, and partnerships into a queryable dataset. This addresses a fragmentation problem in longevity research and investment where critical market intelligence has been scattered across multiple sources.
Amazon makes longevity move with Lifeforce collab
Amazon One Medical has integrated Lifeforce's biomarker analysis into its primary care platform, offering members personalized health insights derived from over 50 standard lab biomarkers organized by health domains. This integration represents a significant expansion of preventive medicine tools into mainstream primary care, positioning biomarker-driven interpretation as a foundational element of personalized health management.
Human brain aging decoded through living tissue
Researchers mapped how living human brain cells coordinate structural changes across the lifespan, revealing that brain aging is an active, regulated biological process rather than passive deterioration. This represents the first large-scale analysis of living tissue, enabling identification of molecular targets for intervention in age-related neurological decline.
MDLifespan and Cenegenics expand toxin-clearing therapy
MDLifespan and Cenegenics are expanding access to Therapeutic Plasma Exchange (TPE), a procedure that removes environmental toxins, microplastics, and heavy metals from circulation to reduce chronic inflammation. The partnership positions toxin clearance as a foundational longevity strategy, addressing inflammation that undermines cognitive, metabolic, and cardiovascular function.
Telomere Shortening Drives Atrial Fibrillation Through VCAM‐1 Mediated Atrial Electrical and Structural Remodeling
Telomere shortening drives atrial fibrillation through VCAM-1 upregulation, which promotes atrial fibrosis and electrical dysfunction. Blocking VCAM-1 reverses these changes and reduces AF susceptibility by 30%, identifying a mechanistic pathway linking cellular aging to arrhythmia risk.
Cumulus Neuroscience expands into Japan with Shionogi collaboration
Cumulus Neuroscience has partnered with Japanese pharmaceutical company Shionogi to deploy its NeuLogiq Platform—an AI-based digital biomarker system—in clinical trials measuring neurophysiological and cognitive function with greater sensitivity and objectivity than traditional assessments. This expansion into Asia reflects the growing adoption of digital endpoints to accelerate central nervous system drug development and early detection of cognitive changes.
Loyal raises $100m Series C to advance canine longevity drug
Loyal secured $100 million Series C funding to advance LOY-002, a prescription medication designed to extend healthy lifespan in senior dogs by targeting metabolic pathways associated with aging. The drug has completed enrollment in its pivotal clinical trial and represents a potential first-in-species FDA-authorized longevity therapeutic.
Protac market set for rapid growth through 2034 amid targeted therapy demand
PROTACs—molecules that selectively degrade disease-causing proteins via the cell's natural ubiquitin-proteasome system—represent a mechanistic departure from traditional inhibitor-based therapies. The market is forecast to expand significantly through 2034, driven by 90 protein-degradation leads in development and pipeline expansion across oncology, neurodegenerative, and inflammatory indications.
Nuritas debuts PeptiStrong wellness prototypes at Expo West
Nuritas is presenting PeptiStrong functional food prototypes containing AI-identified bioactive peptides from natural food sources, designed to support metabolic health, muscle maintenance, and stress regulation through familiar consumer formats like yogurt and beverages. The approach represents an effort to translate precision peptide science into accessible mainstream wellness products.
HepaRegeniX completes Phase Ib study of HRX-215 after minor liver resection
HepaRegeniX completed Phase Ib testing of HRX-215, an oral MKK4 inhibitor designed to enhance hepatic regeneration after surgical resection. Early safety data support advancement to major resection cohorts, potentially expanding surgical candidacy for high-risk patients with limited regenerative capacity.
Host Oxidative Response Capacity Determines Longevity Outcomes of Microbial Interventions
Host genetic capacity to manage oxidative stress determines whether microbiota interventions extend or shorten lifespan. Individuals with genetic variants affecting redox buffering show accelerated aging when exposed to the same microbial signals that promote longevity in genetically robust hosts. This finding establishes oxidative stress management as the critical variable in microbiome-driven aging outcomes.
The Immunogenicity of Human Senescent Cells Is Dependent on the Senescence Inducer and Cell Type
Senescent cell immunogenicity varies substantially by cell type and the trigger that induced senescence. RAS-induced senescent myoblasts activated immune responses, while senescent fibroblasts, endothelial cells, and lung progenitors showed limited or no immunogenicity despite expressing senescence markers.
Adipose‐Specific GHR Deletion Attenuates Brain Aging and Cognitive Decline in Aged Mice
Blocking growth hormone signaling specifically in adipose tissue reduces neuroinflammation, preserves synaptic integrity, and improves cognitive performance across multiple domains in aged mice. This identifies peripheral adipose tissue as an unexpected regulator of brain aging, suggesting a therapeutic target for age-related cognitive decline.
Blood-based AT(N) biomarkers for Alzheimer’s disease and frontotemporal lobar degeneration in Latin America
Plasma biomarkers (phosphorylated tau, amyloid-beta, and neurofilament light) accurately distinguish Alzheimer's disease from frontotemporal lobar degeneration across Latin American populations when integrated with neuroimaging and machine learning algorithms. This addresses a critical gap in early detection capability for underrepresented populations.
Association of brain age gap with BMD and incident fractures in the UK Biobank
Accelerated brain aging—measured as the difference between chronological age and brain imaging markers—correlates with lower bone mineral density and increased fracture risk independent of chronological age. This suggests neurobiological aging patterns may predict skeletal fragility and fracture vulnerability in midlife and older adults.
Creating CAR-T Cells Using Current Alzheimer’s Antibodies
Researchers engineered CAR-T cells using existing Alzheimer's antibodies (lecanemab) to directly target and clear amyloid-beta plaques in mouse models. A transient dosing approach reduced microglial activation and amyloid burden throughout the brain, suggesting this strategy may improve upon current monoclonal antibody therapies.
Wegovy gets cheaper – but at what cost to patients?
As GLP-1 drug prices fall through government programs and compounded alternatives, the FDA warns of safety risks in unapproved formulations—including dosing errors, improper storage, and hospitalizations. The accessibility gains must be weighed against supply chain integrity and long-term health outcomes that depend on consistent, verified dosing.
Genflow reveals early data from SIRT6 gene therapy trial in dogs
Genflow's SIRT6 gene therapy demonstrated superior survival and functional improvements in aged beagles across multiple endpoints, including muscle preservation, frailty reduction, and quality of life measures. This interim data from a proof-of-concept trial establishes preliminary evidence that SIRT6 activation may mitigate age-related functional decline, with potential implications for human therapeutic development.
Brain ‘recycling’ map traces disease risk
Stanford researchers created the first comprehensive atlas of lysosomal proteins across four major brain cell types, revealing cell-specific patterns that explain how waste accumulation contributes to Alzheimer's, Parkinson's, and other neurodegenerative diseases. This cellular-level mapping shifts neurodegeneration research toward early prevention rather than late-stage intervention, with direct implications for maintaining cognitive function across the lifespan.
This MRI doesn’t wait until brain surgery is over
Intraoperative MRI technology enables surgeons to image the brain during active neurosurgery, reducing procedure time by one to two hours and allowing real-time adjustments based on functional data rather than preoperative imaging. This capability addresses a fundamental constraint in neurosurgical care: the gap between what the surgeon sees at the start of an operation and the patient's actual physiological state during intervention.
Broad Epigenetic Shifts in the Aging Drosophila Retina Contribute to Its Altered Diurnal Rhythmic Transcriptome
Aging retinas undergo extensive epigenetic reprogramming affecting approximately 40% of rhythmically expressed genes, driven primarily by decreased histone H3K4 methylation rather than changes to core circadian clock factors. These chromatin-level shifts disrupt the diurnal transcriptional rhythms critical for retinal function and systemic circadian synchronization.
A Multidomain Lifestyle Intervention Is Associated With Improved Functional Trajectories and Favorable Changes in Epigenetic Aging Markers in Frail Older Adults: A Randomized Controlled Trial
A 6-month multidomain lifestyle intervention combining nutritional support and supervised exercise slowed epigenetic aging markers and improved physical function in frail adults over 80, with measurable reductions in biological aging indicators. The findings suggest that coordinated lifestyle strategies can alter the trajectory of age-related decline at the molecular level, not merely at the symptomatic level.
Secretome Profiling of Young Multipotent Stem Cells Reveals Angiogenic and Immunomodulatory Mechanisms Supporting Aged Neuromuscular Health
Young muscle-derived stem cells secrete pro-angiogenic and immunomodulatory proteins that decline with age. Systemic transplantation of these young cells into aged mice restored neuromuscular structure and function through paracrine signaling, with effects sustained for two months.
AI, genomics and CRISPR signal a new phase of biological innovation
AI-driven pattern recognition combined with expanded genomic sequencing and CRISPR gene editing is accelerating drug discovery and precision medicine by generating large datasets for machine learning models. This convergence enables shorter development cycles and more targeted therapeutic interventions based on individual genetic profiles.
p62/SQSTM1 Condensation Modulates Mitochondrial Clustering to Participate in Mitochondrial Quality Control
p62 protein condensation drives clustering of damaged mitochondria during selective autophagy, acting as a quality control mechanism that slows mitochondrial turnover. ALS/FTD-associated mutations disrupt this clustering process, impairing the cell's ability to manage dysfunctional mitochondria—a hallmark of age-related neurodegeneration.
Life Time opens first athletic country club of 2026 in West Cary
Life Time opened a 92,000-square-foot athletic country club in West Cary, North Carolina, featuring pools, fitness studios, pickleball courts, and recovery amenities designed to support comprehensive health and wellness. The facility reflects market demand for integrated health experiences beyond traditional gym offerings.
Virtual assistant enhances health outcomes in older adults with type 2 diabetes
A randomized controlled trial found that older adults with type 2 diabetes using a conversational AI virtual assistant achieved significantly better glycemic control and medication adherence compared to standard care. The intervention demonstrates that digital tools can reduce barriers to diabetes management in aging populations.
Clonal hematopoiesis boosts response to immune checkpoint therapy
Clonal hematopoiesis—the age-related expansion of mutant blood cell populations—enhances response to immune checkpoint inhibitors in cancer patients. This unexpected finding reframes a hallmark of aging as potentially protective in the context of immunotherapy, with implications for how we interpret immune aging and treatment efficacy.
UK Biobank gains physician data for earlier disease signals
UK Biobank has gained access to coded general practice records for 500,000 English volunteers, integrating longitudinal primary care data—diagnoses, prescriptions, referrals, and lab results—into its existing genomic and hospital episode data. This access captures disease trajectories at their earliest clinical detection, enabling researchers to study multimorbidity onset and progression years before hospital admission.
Loyal raises $100m as canine longevity drug nears approval
Loyal has raised $100 million in Series C funding as its lead candidate LOY-002, designed to extend healthy lifespan in dogs, approaches FDA Expanded Conditional Approval. The company has completed two of three major technical requirements and enrolled over 1,300 dogs in its pivotal STAY trial, positioning the first potential FDA-approved longevity drug for market readiness.
Pandorum lands $18m to advance ‘programmable regenerative medicine’
Pandorum Technologies closed an $18 million Series B round to advance exosome-based therapies designed to modulate tissue state away from inflammatory and fibrotic conditions toward functional recovery. The platform targets corneal opacity initially, with applications potentially extending across multiple organs affected by inflammatory and degenerative disease.
New gene map sheds light on muscle loss in aging
Researchers have mapped 250 genes essential for human muscle fiber formation using a CRISPR screening platform, identifying previously unknown genetic drivers of muscle development and linking 41 of these genes to developmental muscle defects. This foundational knowledge directly informs understanding of sarcopenia and age-related muscle loss, where the same fusion mechanisms that fail in rare genetic disorders deteriorate progressively with age.
New retinal screening targets Alzheimer’s before memory loss
Researchers at Oregon Health & Science University are developing a retinal screening tool using fluorescent eye drops to detect amyloid proteins associated with Alzheimer's disease before memory loss occurs. This approach could enable population-level screening in routine ophthalmology clinics, identifying individuals at risk when emerging treatments are most effective.
Young Microbes Rejuvenate Intestinal Function in Mice
Transferring microbiota from young mice to aged mice restored Wnt signaling in intestinal crypts and improved the regenerative capacity of intestinal stem cells. This demonstrates that age-related decline in intestinal function can be partially reversed through microbial transfer, with direct implications for understanding how microbiota composition influences tissue regeneration during aging.
[Feature] Highlights of the SIOG Annual Conference 2025
The 25th SIOG conference highlighted the critical gap in clinical trial representation of older adults with cancer, with calls for expanded inclusion protocols and age-appropriate model testing. This directly affects treatment efficacy data and personalized care decisions for a population representing the majority of cancer diagnoses.
Architect of Frailty Biology and Champion of Translational Geroscience
Jeremy Walston's work established frailty as a biologically coherent condition rooted in chronic inflammation, mitochondrial dysfunction, and impaired stress responsiveness rather than inevitable aging. His translational research framework has advanced clinical intervention strategies and shaped how geroscience addresses loss of physiologic reserve across aging populations.
Anavex Life Sciences reports fiscal 2026 first-quarter results and updates pipeline
Anavex Life Sciences reported improved financial position with reduced operating losses and expanded cash runway, positioning the company to advance its lead Alzheimer's candidate blarcamesine through regulatory pathways while expanding a pipeline addressing multiple neurodegenerative and neuropsychiatric disorders.
Life sciences analytics market to reach $23.17b by 2033
The global life sciences analytics market is projected to double from $11.1 billion in 2024 to $23.17 billion by 2033, driven by AI-enabled drug discovery, clinical trial optimization, and precision medicine workflows. This infrastructure expansion directly influences how treatments are identified, validated, and personalized to individual patients.
Pandorum Technologies raises $18M Series B to scale regenerative therapies
Pandorum Technologies secured $18 million in Series B funding to scale its programmable tissue engineering platform for wound healing and organ repair. The capital accelerates manufacturing, regulatory pathways, and clinical partnerships for regenerative therapies addressing tissue damage and loss.
Sky Labs launches ring-type wearable blood pressure monitor for hospitals
Sky Labs has developed CART, a ring-worn wearable that enables continuous, non-invasive blood pressure monitoring in hospital settings without traditional cuffs. This technology extends real-time hemodynamic tracking from intensive care units to general wards, improving early detection of cardiovascular changes and reducing clinical workload.
Implementing a nationwide healthy longevity program for older adults
France has implemented a nationwide integrated care program (ICOPE) for older adults that prioritizes functional capacity and well-being over disease management alone. This person-centered approach offers a scalable model for other nations seeking to optimize health outcomes in aging populations.
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease
BIIB080, an antisense oligonucleotide targeting tau protein aggregation, demonstrated favorable trends in slowing cognitive and functional decline in a phase 1b trial of mild Alzheimer's disease patients. These exploratory findings support progression to larger efficacy trials and represent a mechanistic approach to tau-mediated neurodegeneration.
[Articles] Prevalence of death in people with vision impairment from cataracts before treatment: a case study from Kenya
Untreated cataracts in Kenya correlate with elevated mortality risk, independent of the vision loss itself. The analysis demonstrates that cataract surgical capacity and access barriers represent a critical public health intervention point for reducing both blindness and premature death.
CagriSema and retatrutide signal the next GLP-1 arms race
Triple and dual agonist drugs like retatrutide and CagriSema target multiple metabolic pathways simultaneously, producing weight loss exceeding 20-30% in clinical trials. These medications represent a shift toward precision metabolic intervention, with implications for both obesity management and aging-related cellular stress.
Smart earbuds bring EEG sleep modulation to consumers
NextSense has commercialized in-ear EEG earbuds that move beyond sleep tracking to real-time neural modulation, using closed-loop audio stimulation timed to reinforce slow-wave sleep. This represents a shift from passive measurement to active intervention in a domain central to longevity—though validation across heterogeneous populations and safety protocols remain open questions.
Half of how long we live might be in our genes
A twin-based study published in Science estimates genetic influence accounts for approximately 55% of human lifespan variation, with the remaining 45% shaped by diet, exercise, habits, and environmental factors. This finding reframes longevity as neither purely genetic nor purely behavioral, but rather a composite outcome where lifestyle interventions remain substantively meaningful within genetically-established boundaries.
Sleep Deprivation Affects Cognition via Myelin Loss
Sleep deprivation causes myelin thinning through cholesterol dysregulation in oligodendrocytes, impairing neural signal transmission and cognitive function. Restoring cholesterol redistribution via cyclodextrin intervention reverses these structural and functional deficits, suggesting a mechanistic pathway linking sleep loss to neurodegeneration.
Danish startup aims to remove ‘forever chemicals’ from the body
Cambiotics is developing a precision probiotic supplement designed to enhance the body's natural clearance of PFAS (per- and polyfluoroalkyl substances) by leveraging specific gut bacterial strains that bioaccumulate these persistent compounds. With €4 million in seed funding secured, the company is preparing human clinical trials targeting populations with elevated PFAS exposure, addressing a widespread chemical burden implicated in liver damage, thyroid disease, and cancer risk.
VectorY doses first patient in ALS gene therapy trial
VectorY Therapeutics has dosed the first patient in a Phase 1/2 trial of VTx-002, a gene therapy designed to sustain antibody production against pathological TDP-43 protein in ALS. This represents a shift from symptomatic management toward addressing the underlying biology of neurodegeneration, with implications for protein aggregation disorders across aging.
[Review] A global gap in autonomy assessment among older adults: a COSMIN systematic review
Autonomy—the capacity to make decisions and direct one's own care—is foundational to healthy aging and person-centered medicine, yet clinical assessment tools for autonomy in older adults remain fragmented and poorly standardized globally. This systematic review of 116 studies across 42 countries identified 50 measurement instruments and evaluated them for validity and reliability, exposing significant gaps in how autonomy is measured and monitored in clinical practice.
Nursing Home Outcomes Following the CareGivers NC Program: A Multi-Year Evaluation of Staffing and Quality Performance
The CareGivers NC program, a state-level workforce intervention addressing certified nursing assistant shortages in North Carolina nursing homes, demonstrates measurable improvements in staffing retention and quality outcomes over multiple years. Staffing stability directly influences care quality, infection rates, and resident health trajectories in congregate settings.
Biohacking market projected to top US$216 billion by 2035
The global biohacking market is projected to grow from US$38.05 billion in 2025 to US$216.68 billion by 2035, driven by consumer demand for self-tracking, personalized health optimization, and continuous sensing technologies. This expansion reflects a shift from consumer fitness gadgets toward clinical-grade diagnostics and subscription-based health management integrated into daily life.
4DMT completes enrollment for phase 3 trial of 4D-150 in wet AMD
4D Molecular Therapeutics completed enrollment for 4FRONT-1, a Phase 3 trial of 4D-150, a gene therapy designed to deliver sustained anti-VEGF treatment to the retina via single injection in wet age-related macular degeneration. The trial enrolled over 500 patients ahead of schedule, with topline results expected in the first half of 2027.
Breye Therapeutics reports strong early data for danegaptide in retinal disease
Danegaptide, an oral small molecule in Phase 1b trials, demonstrated tolerability and early clinical activity in 24 patients with diabetic retinopathy, showing reduced vascular leakage and macular edema over four weeks. The mechanism—stabilizing retinal vasculature against glucose-induced capillary breakdown—addresses a primary pathology in diabetic eye disease, with advancement to Phase 2 planned.
AI-driven bioengineering platforms revolutionize protein design
AI-driven bioengineering platforms are accelerating protein design and drug discovery by computational screening of millions of proteins and billions of compounds annually, reducing traditional wet-lab timelines. This technological shift reshapes how therapeutic candidates are identified and optimized, with governments globally investing multibillion-dollar programs to scale these capabilities.
Frailty phenotype reveals heterogeneity in aging and distinct taurine associations
Aging presents distinct phenotypic pathways with different metabolic signatures, particularly involving taurine metabolism. Identifying these heterogeneous frailty patterns enables targeted intervention strategies rather than one-size-fits-all approaches to age-related decline.
[Articles] Delirium and adverse clinical outcomes: a matched cohort study in the UK Biobank
In-hospital delirium shows a dose-responsive association with adverse long-term clinical outcomes independent of frailty or pre-existing dementia, positioning it as a marker of sustained vulnerability rather than a transient acute event. This distinction matters for risk stratification and post-discharge intervention planning.
Longevity Show announces first partners for 2026
The 2026 Longevity Show has announced its first partners, representing a shift in how longevity research is being translated into clinical practice and consumer applications. The roster spans diagnostics, nutrition, regenerative medicine, AI, and clinical services—signaling a field consolidating around integrated systems that deliver measurable health outcomes rather than isolated interventions.
Restoring the Strength of Natural Killer Cells
Natural killer cells from older adults show reduced capacity to eliminate senescent and cancer cells due to impaired granule release and cytotoxic machinery, not recognition defects. Targeting elevated Cdc42 protein and restoring microtubular organization represents a potential intervention to restore NK cell function with age.
Is longevity ethical? A conversation the industry can’t avoid
This discussion reframes longevity from a pursuit of extreme lifespan extension toward a more grounded question: who benefits from living well longer, and under what conditions? The conversation bridges clinical evidence with ethical policy, arguing that longevity science should be evaluated by the same standards of safety, equity, and access applied to other medical fields.
Aerska lands $39m to advance genetic medicines to the brain
Aerska has secured $39 million in Series A funding to advance RNA interference therapies that cross the blood-brain barrier for neurodegenerative diseases including Alzheimer's and Parkinson's. The company's platform addresses a critical delivery bottleneck that has limited genetic medicine effectiveness in the central nervous system.
Twenty years on, cognitive training shows dementia signal
A 20-year follow-up of the ACTIVE trial found that speed-of-processing training with booster sessions reduced dementia diagnoses in older adults, a rare signal of efficacy in prevention research anchored to clinical diagnoses rather than cognitive test scores alone.
New peptide drugs on the horizon with PepLib–Lilly collab
Eli Lilly and PepLib Biotech have formed a collaboration to develop peptide-based therapeutics designed to target specific disease pathways with precision. Peptides represent a distinct therapeutic modality with applications in age-related conditions, metabolic dysfunction, and cardiovascular disease—key drivers of healthspan and lifespan limitations.
A Mixed-Methods Study of End-of-Life Care in Assisted Living During the COVID-19 Pandemic: National Survey of Administrators and In-Depth Interviews With Bereaved Next of Kin
This mixed-methods study documents end-of-life care policies in assisted living facilities during peak COVID-19, revealing gaps between administrative compliance and families' experiences of care quality. The findings underscore how systemic constraints during crisis periods compromise the dignity and continuity of end-of-life support.
Plasma Proteome Profiling of Centenarian Across Switzerland Reveals Key Youth‐Associated Proteins
Plasma proteomics of Swiss centenarians identified 37 proteins maintaining a younger profile despite advanced age, with pathways implicating immune regulation, metabolic enzyme function, and extracellular matrix stability. These findings establish reproducible molecular signatures of healthy longevity across independent cohorts and suggest specific protein targets for aging intervention.
Overactivation of Cdc42 GTPase Impairs the Cytotoxic Function of NK Cells From Old Individuals Towards Senescent Fibroblasts
Natural killer cells from older adults fail to clear senescent fibroblasts due to overactivation of the Cdc42 protein, which disrupts the cellular machinery required for releasing cytotoxic granules and producing ATP. Pharmacological inhibition of Cdc42 restores this clearing capacity and offers a potential therapeutic target for age-related disease driven by senescent cell accumulation.
Rapamycin Reverses the Hepatic Response to Diet‐Induced Metabolic Stress That Is Amplified by Aging
Aging amplifies the liver's inflammatory and metabolic response to high-fat diet, increasing hepatic steatosis and transcriptional dysregulation. Rapamycin treatment reversed most diet-driven gene expression changes in older mice, reducing steatosis, body weight gain, and markers associated with liver disease progression.
PrimeGen US to merge with DT Cloud Star in $1.5B SPAC deal
PrimeGen US, a regenerative medicine company developing stem cell and exosome therapies, is merging with a SPAC at a $1.5 billion valuation to advance clinical trials for acute liver injury and related conditions. The capital infusion targets acceleration of regulatory pathways and commercialization of cell-based treatments grounded in two decades of proprietary stem cell research.
Serotonin Anti-Aging Center to open Lake Nona location this spring
Serotonin Anti-Aging Centers is expanding to Lake Nona, Florida in spring 2026, adding to its national footprint of longevity and hormone optimization clinics. The expansion reflects growing consumer demand for preventive wellness services, though the article focuses on business development rather than clinical evidence.
Sky Labs secures exclusive CART BP pro distribution with Otsuka in Japan
Sky Labs secured exclusive distribution rights with Otsuka Pharmaceutical to bring CART BP pro, a cuffless blood pressure monitor using photoplethysmography technology, to Japanese hospitals and clinics. The device enables continuous 24-hour blood pressure monitoring without traditional cuffs, addressing a market of 43 million hypertensive Japanese patients where many remain uncontrolled or undiagnosed.
Insilico Medicine appoints Halle Zhang as vice president of clinical development, oncology
Insilico Medicine appointed Halle Zhang, PhD, as Vice President of Clinical Development for Oncology, bringing 20+ years of experience across academia, biotech, and pharmaceutical firms. The appointment reflects the company's strategy to combine AI-driven drug discovery with clinical expertise as multiple AI-designed oncology candidates enter Phase I trials.
VectorY Therapeutics appoints Kevin Pojasek to board of directors
VectorY Therapeutics appointed Kevin Pojasek, an experienced biopharma executive, to its board to advance vectorized antibody therapies for neurodegenerative diseases including ALS, Huntington's disease, Alzheimer's disease, and frontotemporal dementia. This leadership addition supports the company's clinical development strategy in a therapeutically significant space.
Correction to “Photobiomodulation Suppresses JNK3 by Activation of ERK/MKP7 to Attenuate AMPA Receptor Endocytosis in Alzheimer's Disease”
A correction to prior research on photobiomodulation's mechanism in Alzheimer's disease clarifies the molecular pathway by which light exposure modulates neuroinflammatory signaling. The finding reinforces the relevance of non-pharmacological interventions targeting neurodegeneration at the cellular level.
First Human Cellular Reprogramming Trial Cleared by the FDA
Life Biosciences has received FDA clearance to begin the first human trial of cellular reprogramming, testing ER-100 against age-related vision diseases. This represents the first clinical translation of partial reprogramming technology, moving a three-decade research program from laboratory validation into human application.
Rapamycin and the quiet work of immune repair
Low-dose rapamycin protects DNA in aging immune cells by reducing damage-induced cell death and senescence markers, suggesting mTOR inhibition preserves immune resilience through direct genoprotection rather than broad immunosuppression. This mechanistic clarity offers a more tractable regulatory and therapeutic pathway than the traditional anti-aging framing.
Pfizer’s monthly obesity drug shows promise, spooks investors
Pfizer's PF-3944 demonstrated 11-12 percentage points greater weight loss than placebo in Phase 2b trials with monthly dosing, maintaining efficacy without plateau at 28 weeks. The drug's clinical promise is offset by higher discontinuation rates due to gastrointestinal side effects and direct comparison disadvantage relative to competitor therapies.
Angitia Bio lands $130m to advance human trials of musculoskeletal health drugs
Angitia Biopharmaceuticals secured $130 million to advance clinical trials of biologic therapies for musculoskeletal diseases, with a Phase 2 osteoporosis candidate targeting dual suppression of bone formation inhibitors in postmenopausal women. This dual-target approach addresses a significant gap in current osteoporosis treatment efficacy and tolerability, with topline results expected in 2027.
Insilico lands $5m as AI-designed drug hits first-in-human milestone
Insilico Medicine's AI-designed drug candidate MEN2501 has advanced to first-in-human dosing in a Phase 1 trial, triggering an $5 million milestone payment and validating generative AI's capacity to compress drug discovery timelines from years to months. The molecule targets chromosomal instability in solid tumors—a mechanism relevant to cellular aging—and represents a proof-of-concept for AI-driven identification of therapeutic candidates.
Designing therapies patients can live with
Light-activated photodynamic therapy for cutaneous T-cell lymphoma demonstrates a treatment design principle critical to chronic disease management: therapies must be engineered for decades of safe, repeatable use rather than optimized solely for efficacy. For conditions that persist across a lifespan, cumulative toxicity and patient burden become as clinically significant as the primary disease.
Oncolytic virus clinical trial landscape expands with 100+ companies
Over 100 companies are advancing oncolytic virus therapies through clinical development, with 110+ candidates targeting solid tumors through mechanisms that combine direct cancer cell destruction with immune system activation. This expansion reflects maturation of viral engineering and increased confidence in immunotherapy approaches to cancer treatment.
LifeVantage reports results of Q2 fiscal 2026
LifeVantage reported Q2 fiscal 2026 revenue of $48.9 million, down 27.8% year-over-year, primarily due to declining MindBody GLP-1 System sales partially offset by the LoveBiome acquisition. The company maintains profitability and cash position while adjusting its product portfolio.
Cognision launches cognision360 platform for CNS trial biomarkers
Cognision360 consolidates neurobiomarker data collection and analysis for CNS clinical trials through automated workflows and standardized integration of EEG, sleep, eye tracking, wearables, and cognitive assessments. The platform addresses fragmentation in multi-site studies and accelerates regulatory pathways by improving data integrity and reducing manual processing errors.
Telomir Pharmaceuticals reports new data on epigenetic modulation mechanism
Telomir-1 (Telomir-Zn) modulates intracellular metal balance by increasing zinc and reducing iron, influencing epigenetic regulation and cellular stability without triggering cytotoxic stress. This mechanism addresses oxidative stress and genomic integrity pathways implicated in aging and cancer biology.
Cell and gene therapy market shows $1.2B Zolgensma and $1.5B Yescarta sales
The cell and gene therapy market demonstrates commercial maturation with Zolgensma generating $1.2 billion and Yescarta $1.5 billion in annual sales, reflecting regulatory acceptance of 46 FDA-approved CGT products. This market trajectory indicates that genetic and cellular interventions are transitioning from experimental to established therapeutic options for previously intractable genetic disorders and certain cancers.
Similar minds age alike: an MRI similarity approach for predicting age-related cognitive decline
Brain structural similarity patterns on MRI predict individual rates of cognitive decline better than chronological age alone, suggesting that neural architecture itself encodes aging trajectories. This offers a measurable biological marker for identifying cognitive vulnerability before clinical decline becomes apparent.
Increasing Senolytic Effectiveness by Stressing Mitochondria
Mitochondrial stress emerges as a critical mechanism underlying senolytic effectiveness against senescent cells. This finding suggests that the therapeutic benefit of senolytics depends partly on their capacity to induce cellular energy stress, offering a framework for optimizing drug selection and combination strategies in senescence-targeted interventions.
Sex Differences in Associations Between Adversity and Biological Ageing
Childhood adversity associates with accelerated biological aging markers primarily in women, while adulthood adversity shows stronger associations with aging markers in men. This sex-specific pattern suggests distinct windows of physiological vulnerability across the lifespan that warrant consideration in aging research and clinical intervention timing.
‘Our mission is to bring longevity to everyone’
Ambr's explainable AI platform integrates clinical data, biomarkers, and lifestyle information to help primary care physicians identify patient health trajectories and intervene with preventive strategies before disease develops. The approach targets population-level prevention through existing healthcare infrastructure rather than direct-to-consumer channels, addressing the gap between longevity science and routine clinical practice.
Mair targets Parkinson’s biology via Radboud University tie-up
Mair Therapeutics and Radboud University are collaborating to develop small molecules that enhance TMEM175, a lysosomal ion channel, to restore cellular waste clearance in Parkinson's disease. This approach targets early cellular dysfunction before neuronal damage becomes irreversible, addressing a fundamental mechanism of neurodegeneration.
Biopeak’s longevity care earns repeat investor support
Biopeak, India's longevity care platform, secured $2.7 million in follow-on funding, demonstrating investor confidence in its longitudinal health optimization model. The company has progressed from concept to clinical delivery, addressing a gap in preventive care infrastructure within India's healthcare system.
Hair regrowth biotech raises $256m in ‘upsized’ IPO
Veradermics raised $256 million in its IPO for VDPHL01, an extended-release oral minoxidil formulation designed to maintain steady hair follicle exposure while reducing cardiac side effects associated with immediate-release formulations. Phase 3 trials are underway to validate whether sustained drug delivery improves hair regrowth outcomes compared to existing topical and oral alternatives.
Weight returns fast after quitting GLP-1 drugs, study and experts say
Weight loss achieved through GLP-1 medications returns rapidly after discontinuation—approximately one pound per month, with most patients regaining initial weight within two years. This rebound occurs nearly four times faster than weight regain following diet or exercise cessation, underscoring that pharmacological intervention without sustained lifestyle modification produces temporary rather than durable health outcomes.
Lifespan and Fecundity Impacts of Reduced Insulin Signalling Can Be Directed by Mito‐Nuclear Epistasis in Drosophila
Reduced insulin signaling extends lifespan in Drosophila, but the effect—beneficial or detrimental—depends on the genetic interaction between mitochondrial and nuclear DNA. This reveals that conserved aging mechanisms operate differently across individuals based on mito-nuclear epistasis, with direct implications for personalized longevity interventions.
Isaac Health partners with NYU Langone to expand brain health care access
Isaac Health and NYU Langone have established a telehealth partnership to accelerate access to dementia and cognitive evaluation services, addressing critical delays in specialist availability across New York state. The hybrid model reduces diagnostic timelines from months to days while maintaining the option for in-person intervention when clinically indicated.
Abinopharm releases AbinoNutra® NMN white paper after FDA reinstatement and clinical evidence
Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.
Alzheon reports biomarker results supporting ALZ‑801 effects in Alzheimer’s
Alzheon's ALZ-801 demonstrated sustained reductions in plasma phosphorylated tau 217 across Phase 2 and Phase 3 trials, with biomarker changes correlating to cognitive preservation and protection against hippocampal volume loss in early Alzheimer's disease. These results support the compound's mechanism of inhibiting neurotoxic amyloid oligomer formation at disease stages where intervention may be most effective.
dōTERRA founder David Stirling returns as Chief Executive Officer
dōTERRA announced that founder David Stirling has resumed his role as Chief Executive Officer after a two-year absence. The leadership transition occurs as the essential oils and wellness company navigates economic headwinds and shifts in the direct sales market.
Insilico Medicine secures $5 M milestone from Menarini after FIH dosing
Insilico Medicine received a $5 million milestone payment from Menarini Group following first-in-patient dosing of MEN2501, an AI-discovered KIF18A inhibitor targeting chromosomal instability in cancer. The achievement demonstrates the translation of computationally designed oncology candidates into clinical validation.
The pursuit of understanding human longevity
Extreme longevity does not require genetic predisposition to exceptional health; rather, it emerges from multifactorial resilience combining protective genetics, metabolic efficiency, low systemic inflammation, and sustained lifestyle choices. This reframes centenarian health as an achievable outcome of integrated biological and environmental factors rather than an exceptional outlier.
Longevity capital pauses to think at Davos
The longevity field is maturing from speculative narrative to operational infrastructure, with investors and policymakers converging on evidence-based translation rather than technological spectacle. The shift reflects recognition that sustainable healthspan gains require business models and regulatory frameworks designed for decades-long compounding, not short-term capital cycles.
Fitbit founders put family first in new health monitoring startup
Luffu, a new app from Fitbit co-founders Park and Friedman, monitors collective family health by tracking changes in individual rhythms over time through integrated data from devices, medical records, and daily observations. The product addresses evidence that strong family relationships provide physiological protection comparable to major lifestyle interventions, integrating relational health into the longevity conversation.
Study finds ‘back door’ that worsens arthritis inflammation
Researchers have identified TWEAK and its receptor Fn14 as an alternate inflammatory pathway that allows arthritis inflammation to persist even when TNF inhibitors block the main inflammatory signal. This explains why 30-40% of patients fail to respond adequately to blockbuster TNF-blocking drugs and points toward combination therapies targeting multiple pathways simultaneously.
Association Between Vitamins and Slower Biological Aging
A large epidemiological analysis of 15,050 participants found that higher intake of vitamins, particularly C and B2, correlates with slower biological aging as measured by multiple aging biomarkers. The association remained significant after adjustment for socioeconomic and lifestyle factors, suggesting a direct relationship between vitamin adequacy and the rate of biological aging.
Salvo Health closes $8.5m for new chronic gut care model
Salvo Health secured $8.5 million in Series A funding to build a hybrid care model addressing chronic gastrointestinal and metabolic conditions through team-based support for gastroenterologists. The company treats gut health as a multisystem process unfolding over months and years, positioning itself as an infrastructure layer that enables primary care practices to deliver continuous, personalized care without replacing physician judgment.
Jupiter Neurosciences expands Nugevia addressable market with focus on GLP‑1 users
Jupiter Neurosciences is positioning its Nugevia supplement line to support individuals using GLP-1 weight-loss medications, targeting the physiological demands these drugs place on mitochondrial function, lean tissue preservation, and metabolic signaling. This represents a market expansion that acknowledges the need for targeted support during rapid metabolic change induced by pharmacological intervention.
Gameto licenses Harvard meiosis IP to advance human ovary‑in‑a‑dish platform
Gameto has licensed Harvard intellectual property enabling early meiosis induction in human cells, advancing an in-vitro ovarian development platform. This technology extends the ability to model complete ovarian biology and may accelerate therapeutic discovery for infertility, menopause, and ovarian insufficiency.
Acorn Biolabs treats first patients in randomized hair regeneration trial
Acorn Biolabs has initiated a randomized, controlled trial of YOU, an autologous secretome derived from hair follicle stem cells, to treat androgenic alopecia. The study will measure changes in hair density, thickness, and patient outcomes against placebo, establishing whether personalized regenerative approaches offer clinically meaningful advantages over existing pharmacologic treatments.
Bexorg secures grant to speed Parkinson’s therapies
Bexorg has secured funding to validate TRPML1, a protein target for Parkinson's therapies, using preserved human brain tissue paired with AI-driven biomarker identification. This approach addresses a critical translational gap: the inability to confirm drug efficacy in human neural tissue, which has caused over 95% of CNS drug candidates to fail in clinical trials despite theoretical promise.
Where are Europe’s oldest people living? What geography tells us about a fragmenting continent
Regional analysis of 450 European regions over 27 years reveals that life expectancy gains remain sustained in leading regions despite broader stagnation, indicating that longevity plateaus are regional and contextual rather than universal biological limits. Geographic disparities in longevity trajectories suggest that environmental, social, and health system factors continue to drive meaningful variation in human lifespan potential.
Novo Nordisk edges closer to EU nod for MASH drug
The European Medicines Agency recommended semaglutide for metabolic dysfunction-associated steatohepatitis (MASH), positioning it as the first GLP-1–based treatment for this silent liver disease in the EU. Approval would represent a significant shift from managing late-stage liver complications to intervening earlier in a metabolic disease that accelerates aging and reduces healthspan.
Living Arrangements and Cognitive Impairment Among Mexican American Older Adults: Nativity Differences
Living arrangement patterns differ significantly between U.S.-born and foreign-born Mexican Americans aged 75+, with distinct associations to cognitive impairment risk. Foreign-born older adults show protective effects from multigenerational households, while U.S.-born counterparts face increased cognitive decline risk when living alone, suggesting nativity shapes how social structure influences neurological reserve.
Making it Work: A Qualitative Study of Nurse Practitioner–Physician Collaboration in Long-Term Care Homes
This qualitative study examines how nurse practitioners and physicians collaborate in long-term care settings to deliver acute, episodic, and palliative care while reducing unnecessary hospitalizations. The research identifies attributes and practices that support effective interprofessional teamwork in these environments.
The age gap of health misinformation
Older adults encounter significantly more low-credibility health information online than younger populations, according to analysis of four weeks of digital trace data. This exposure gap has direct implications for health decision-making and the efficacy of evidence-based interventions in aging populations.
Exposure to low-credibility online health content is limited and is concentrated among older adults
Older adults encounter low-credibility health information online at higher rates than younger populations, though overall exposure remains limited and concentrates among those predisposed to health misinformation. This demographic pattern has direct implications for how aging individuals evaluate and act on health guidance.
Death prediction app launches ‘AI health concierge’
Death Clock has launched Life Lab, an AI-driven health concierge that integrates blood biomarker analysis with personalized preventive guidance to help users close the gap between their current and optimized projected lifespan. The service aggregates laboratory testing, medical records, and wearable data to identify actionable interventions across four major chronic disease categories.
The regulatory path for rescheduling psychedelics for healthspan
Psychedelics show promise for cognitive resilience and neural regeneration, but Schedule I classification creates regulatory barriers that prevent clinical investigation of their healthspan applications. Current drug policy frameworks were designed for acute disease endpoints and cannot adequately evaluate interventions targeting age-related decline over extended timeframes.
AstraZeneca signs $18.5b deal for next-gen slimming drugs
AstraZeneca's $18.5 billion licensing deal with CSPC Pharmaceutical Group targets next-generation obesity therapeutics, particularly SYH2082, designed for improved patient adherence and reduced cardiometabolic complications. Once-monthly dosing and AI-enabled peptide platforms position these agents as tools for sustained weight management and prevention of obesity-related disease burden.
Argo pushes gene-silencing therapy for heart risk into Phase 2b
Argo Biopharma has dosed the first patient in a Phase 2b trial of BW-20829, an siRNA therapy targeting elevated Lipoprotein(a) and atherosclerotic cardiovascular disease. Lp(a) represents a genetically determined cardiovascular risk factor resistant to conventional interventions, making this advance relevant to a significant gap in current therapeutic options for reducing disease burden and extending healthspan.
What new twins study reveals about genes, environment and longevity
A recent twin study published in Science estimates genetic influence on human lifespan at approximately 50%, substantially higher than previous estimates of 25-33%, by accounting for changes in external causes of death such as accidents and infectious disease. This suggests environmental and lifestyle factors carry equal weight to genetics in determining longevity outcomes.
Xella secures $3.7m to put women first in health and longevity
Xella Health has secured $3.7 million in pre-seed funding to build a precision health platform that decodes women's biological signals through menstrual fluid analysis alongside blood testing, combined with longitudinal tracking and clinician guidance. This approach shifts women's healthcare from reactive treatment to early detection and prevention, with direct implications for hormone health, fertility, disease risk stratification, and long-term healthspan outcomes during critical life transitions like perimenopause.
Precision targeting of the SASP in cancer therapy
TGFβ signaling emerges as the primary tumor-promoting mechanism within senescent cells induced by platinum chemotherapy in ovarian and lung cancers. Targeting this pathway selectively could preserve the therapeutic benefit of chemotherapy while blocking its pro-tumor effects, addressing a critical vulnerability in current cancer treatment.
Why precision medicine is changing how we treat aging
Precision medicine approaches that integrate regenerative therapies, peptides, and personalized diagnostics address the cellular foundations of chronic pain and accelerated aging rather than managing symptoms alone. This shift from symptom suppression to root-cause intervention reflects an emerging understanding that dysfunction across multiple physiological domains—inflammation, energy production, cellular cleanup, and tissue regeneration—converges in conditions labeled as chronic pain or age-related decline.
Insilico’s AI obesity drug hits up to 31.3% weight loss
Insilico Medicine's AI-designed drug ISM0676 achieved up to 31.3% weight loss in preclinical studies when combined with semaglutide, with a mechanistic approach targeting metabolic regulation rather than appetite suppression alone. The compound preserved lean muscle mass during weight loss and showed favorable safety and pharmacokinetic properties, suggesting potential advantages over current GLP-1 therapies for sustained metabolic health.
Tau exposure reveals how synapses unravel over time
Brief tau exposure initiates a progressive cascade of synaptic dysfunction over days, with lasting impairment persisting long after the initial toxic insult clears. This temporal trajectory, rather than static pathology accumulation, reframes neurodegeneration as a window for early intervention before synaptic loss becomes irreversible.
PranaX lands $17m to harness exosomes in regenerative biologics
PranaX secured $17 million in Series A funding to develop exosome-based therapeutics licensed from UT MD Anderson, targeting age-related inflammation and tissue degeneration. The company plans to commercialize stem cell-derived exosome products for wellness applications and potentially clinical programs addressing chronic age-related conditions.
Alzheimer’s treatment may soon be home-injectable
The FDA is reviewing LEQEMBI IQLIK, a weekly subcutaneous formulation of lecanemab for early Alzheimer's disease, which may delay cognitive decline by 2.5 to 8 years depending on disease stage. This formulation removes the burden of frequent clinic visits while targeting both amyloid plaques and toxic protofibrils that precede visible neurodegeneration.
Your genes matter more for lifespan now than they did a century ago – here’s why
A new analysis of twin and family data suggests genetic contribution to lifespan variation may be approximately 50–55% in modern developed populations, compared to the long-cited 20–25% figure. This shift reflects changing causes of death—from external threats a century ago to age-related diseases today—not increased genetic influence itself.
Periodic Therapeutic Phlebotomy Mitigates Systemic Aging Phenotypes by Promoting Bone Marrow Function
Periodic therapeutic phlebotomy restores bone marrow function in aging models, reducing senescence markers and improving tissue integrity across multiple organ systems. The mechanism involves rebalancing hematopoietic homeostasis through rescue of mesenchymal and endothelial stem cells, suggesting a practical intervention with clinical translation potential.
Multi‐Omics Analysis of Human Blood Cells Reveals Unique Features of Age‐Associated Type 2 CD8 Memory T Cells
Aging drives accumulation of a distinct CD8 T cell population lacking CXCR3 that exhibits Th2-skewed transcriptional and epigenetic programming. This shift correlates with increased risk for asthma, chronic liver disease, and type 2 diabetes, suggesting age-related immune dysregulation follows a predictable molecular trajectory.
Mesoblast reports Ryoncil® net revenues of US$30 M for the quarter
Mesoblast's Ryoncil® generated US$30 million in net revenues for Q4 2025, with gross sales of US$35 million representing 60% quarterly growth following FDA approval for steroid-refractory acute graft-versus-host disease in pediatric patients. The company secured US$125 million in non-dilutive financing to support label expansion and strategic partnerships.
ProMIS Neurosciences lines up up to $175 M private placement to fund Alzheimer’s trial
ProMIS Neurosciences secured up to $175 million in private investment to fund Phase 1b trials of PMN310, a selective antibody targeting toxic misfolded protein oligomers in Alzheimer's disease. The financing extends the company's operational runway to 2028 and positions completion of a landmark clinical study with interim data expected mid-2026.
NeuroEM Therapeutics appoints Dr. W. Scott Burgin as Chief Medical Officer
NeuroEM Therapeutics appointed Dr. W. Scott Burgin as Chief Medical Officer to advance its transcranial electromagnetic treatment technology for Alzheimer's disease and cognitive decline. The non-drug approach uses wearable devices to modulate neuronal activity and holds FDA Breakthrough Device designation, positioning it as a potential alternative to pharmaceutical interventions in neurodegeneration.
Illumina completes acquisition of SomaLogic, expanding its proteomics and multiomics footprint
Illumina's acquisition of SomaLogic integrates large-scale proteomics technology into genomic sequencing platforms, enabling simultaneous measurement of thousands of proteins alongside DNA analysis. This capability creates a more complete molecular picture of individual health status and disease risk, advancing precision health and biomarker discovery.
Probiotic Lactiplantibacillus plantarum OL3246 supports healthy aging by enhancing quality of life, reducing inflammation, and modulating gut microbiota: a pilot study
A pilot study demonstrates that Lactiplantibacillus plantarum OL3246 improves quality of life in aging adults through measurable reductions in inflammatory markers and shifts in gut microbiota composition. This probiotic strain shows potential as a targeted intervention for mitigating age-related inflammatory decline.